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Sometimes things aren't clear right away. That's where you need to be patient and 
persevere and see where things lead. 
Mary Pierce 
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Abstract 
In the bone marrow (BM), stromal cells create special microenvironments or niches 
indispensable for the maintenance, proliferation and differentiation of haematopoietic 
stem cells (HSCs) and their derivatives, such as B cells. Moreover, evidence suggests 
that the BM microenvironment promotes malignant growth, including acute B 
lymphoblastic leukaemia (B-ALL). Currently, most of the knowledge on the interactions 
occurring in this malignant niche has been provided by in vitro systems and in vivo 
models unable to fully simulate the human BM. We set out to determine if C-X-C motif 
chemokine 12 (CXCL12), vascular cell adhesion molecule 1 (VCAM-1) and interleukin 7 
(IL-7), stroma-derived factors, play a crucial role in B-ALL growth using a novel mouse 
model with subcutaneously implanted ectopic human BM niches downregulated for 
these factors. In vitro preliminary results not only demonstrated the biological importance 
of BM mesenchymal stromal cells (MSCs) and of these factors on B-ALL, but also 
allowed the development of functional assays to test the genetically manipulated MSCs 
produced. As constitutive knock down (KD) of these factors led in most cases to loss of 
in vivo bone forming, we generated human inducible KD MSCs for VCAM-1, IL-7 and 
CXCL12, and validated successful KD of VCAM-1 and IL-7 at mRNA and/or protein 
levels. Furthermore, to test complete ablation of our targets, we developed human knock 
out (KO) MSCs for CXCL12, VCAM-1 and CD44 using the CRISPR/Cas system. A 
decrease at the protein level of CXCL12 and VCAM-1 was observed in KO MSCs, which 
seemed to result in the reduction of adhesion of B-ALL cells to VCAM-1 KO MSCs. Taken 
together, we generated tools that allow the in vivo confirmation of our in vitro data which 
indicates the importance of CXCL12, VCAM-1, IL-7 for B-ALL migration, adhesion and 
growth. Further understanding on the communication between B-ALL cells and the BM 
cellular niches will contribute to the improvement of current as well as to the development 
of novel therapies. 
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Resumo 
As células do estroma presentes na medula óssea (MO) formam microambientes ou 
nichos que são indispensáveis à manutenção, proliferação e diferenciação de células 
estaminais hematopoiéticas, assim como de células que se diferenciam a partir destas, 
como os linfócitos B. O microambiente da MO também favorece e promove o 
crescimento maligno de células cancerígenas, tal como de leucemia linfóide aguda de 
linfócitos B (LLA-B). A maioria das evidências experimentais atuais acerca das 
interações existentes neste nicho provêm de experiências in vitro e de modelos animais 
incapazes de simular totalmente a MO humana. O principal objetivo deste trabalho foi 
determinar se C-X-C motif chemokine 12 (CXCL12), vascular cell adhesion molecule 1 
(VCAM-1) and interleukin 7 (IL-7), fatores derivados do estroma da MO, desempenham 
um papel importante no crescimento de LLA-B, utilizando um novo modelo semelhante 
ao sistema humano. Este modelo consiste na implantação subcutânea em murganhos 
imunodeficientes de nichos de MO que expressam níveis reduzidos de CXCL12, VCAM-
1 e IL-7. Resultados preliminares in vitro demonstraram a importância biológica das 
células mesenquimais do estroma (CME) da MO e dos fatores estudados em LLA-B, e 
permitiram desenvolver ensaios funcionais para testar o efeito de CME geneticamente 
manipuladas. Como a supressão (KD) permanente destes fatores levou à perda da 
capacidade de formar osso in vivo, gerámos CME cujos níveis de VCAM-1, IL-7 e 
CXCL12 podem ser suprimidos de uma forma controlada e validámos a supressão de 
VCAM-1 e IL-7 ao nível do mRNA e da proteína. Para testar o efeito da supressão total 
destes fatores, desenvolvemos CME deficientes em VCAM-1, CXCL12 e CD44 
utilizando o sistema CRISPR/Cas. Foi observado um decréscimo na expressão de 
CXCL12 e VCAM-1 ao nível da proteína e, sob o ponto de vista funcional, a supressão 
dos níveis de VCAM-1 resultou na redução da adesão de células de LLA-B. Em resumo, 
neste trabalho desenvolvemos ferramentas que permitem a confirmação in vivo dos 
nossos resultados obtidos in vitro que sugerem a importância dos fatores estromais 
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VCAM-1, IL-7 e CXCL12 para a migração, adesão e crescimento de LLA-B. Uma melhor 
compreensão da comunicação entre células de LLA-B e os nichos celulares da MO 
permitirá a melhoria das terapias atuais e ainda o desenvolvimento de novos alvos 
terapêuticos. 
 
PALAVRAS-CHAVE: microambiente da medula óssea ∙ fatores derivados de células do 
estroma ∙ leucemia linfóide aguda ∙ modelo de murganho humanizado 
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1. Introduction 
Haematopoietic Stem Cells (HSCs) and their more mature derivatives rely on the cellular 
niches existing in the bone marrow (BM) for support, survival, differentiation and 
proliferation. This complex BM niche comprises many different types of cells, some of 
which include osteoblasts, endothelial cells and mesenchymal cells. These BM-derived 
stromal cells (BMSCs) regulate blood cell behaviour by secreting various molecules and 
by establishing cell-cell contact with them. However, many factors remain unknown 
and/or their function are not fully understood yet in humans (Kaur-Bollinger et al., 2012). 
In addition to this physiological role in haematopoietic differentiation, BMSCs are crucial 
in the creation of an abnormal niche which serves as sanctuary for tumour cells, as 
occurs in B-acute lymphoblastic leukaemia (B-ALL), the most common paediatric cancer 
(Nagasawa, 2006). In this hematologic malignancy, immature B cells accumulate in the 
BM due to their exacerbated and uncontrolled growth, resulting in normal 
haematopoiesis impairment and in the inability to mount a normal immune response. 
Further understanding on the interactions between these leukemic cells and BMSCs 
would enable the development of novel therapies. Targeting them would inhibit leukemic 
cell growth and prevent relapse. So far, most studies were conducted using in vitro 
systems and in vivo animal models that don’t fully resemble the human BM niche. 
Therefore, new animal models have been developed to more closely simulate the human 
BM microenvironment. By making use of such sophisticated models, we may increase 
our knowledge on the stromal factors present in BM and their relative importance in 
supporting B-ALL cell growth, thus contributing to the development and progress of 
therapeutical options. 
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1.1. Niches in the Bone Marrow 
1.1.1.  The Bone Marrow 
The BM is a tissue that occupies the medullary cavities, which are the large central 
cavities of thick and hollow cylinders of compact bone of bone shafts of typical long bones 
(such as the femur or the humerus). Regarding their role in the human organism, the BM 
is a primary lymphoid tissue and the major haematopoietic organ, i.e. the principal place 
responsible for the active production and development of blood cells (erythrocytes, 
granulocytes, monocytes, lymphocytes and platelets) from HSCs, for which you can call 
this their home (Travlos, 2006).  
In terms of spatial composition, the main constituents of BM are the bone and the 
vascular tissues. The endosteum is the inner surface of the BM cavity, consisting of 
cortical and trabecular bone types. Cortical bone is located in the diaphyseal region of 
bone, is thick and dense (80–90% of the bone is calcified) and has mainly mechanical 
and protective functions. On the other hand, trabecular bone is found in the metaphyseal 
region of bone, is less dense (15–25% is calcified) and has a metabolic role. Most studies 
refer to the trabecular region as the preferable anatomical location for HSCs (Calvi et al., 
2003a; Fujisaki et al., 2011; Zhang et al., 2003). Trabecular surfaces are thought to 
establish a connection between the skeletal system and the haematopoietic system. The 
other component of BM is a dense network of thin vessels that allows the passage of a 
large number of blood cells through their endothelium, known as the medullary vascular 
sinuses. Blood cells and their precursors are located in the proximity of these vascular 
sinuses (Lichtman, 1981). 
Besides HSCs and the diverse lineages that arise from them, the BM also contains non-
haematopoietic cells, the stromal cells, which are adherent cells that create special 
microenvironments or niches. The niches give support to the HSCs and blood cells, 
maintaining their viability and supplying them with factors necessary for their survival and 
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differentiation. This concept and the properties of these niches will be reviewed in the 
following sections. 
 
1.1.2.  Haematopoiesis 
As previously mentioned, the cellular components of the blood are produced in the BM. 
These blood cells originate by proliferation and differentiation from HSCs, a subset of 
BM cells. Haematopoiesis, the process of blood cell formation, is possible because of 
the characteristics of HSCs which, as stem cells, are multipotent, i.e. are able to give rise 
to multiple differentiated cell types, and are self-renewing, possessing almost unlimited 
ability to expand themselves without differentiating. Thus, HSCs are a long-term self-
renewing cell population that gives rise to all mature blood and immune cells (Spangrude 
et al., 1988), thereby maintaining the homeostasis of the haematopoietic system, 
important for providing a constant supply of mature blood elements. This continuous 
provision of blood cells is critical as the body daily requires a considerable amount of 
blood cells. (Purton and Scadden, 2008). In adult mammals, this process occurs mainly 
within the BM but it is initiated during the third week of gestation in the yolk sac and only 
by the eleventh week does it shift to BM (Tavian and Peault, 2005). It has been 
suggested that during development, HSCs might migrate from the inner bone surface 
towards the central region of the BM cavity (Hermans et al., 1989; Jacobsen and 
Osmond, 1990; Lord et al., 1975). However, recent reports contradict this view, as they 
describe the existence of dormant HSCs in areas away from the bone surface and close 
to the vasculature (Kunisaki et al., 2013). 
When HSCs lose self-renewal ability they mature into multipotent progenitors (MPPs) 
and become increasingly more differentiated as they become common myeloid 
progenitors (CMPs) or lymphoid-primed multipotent progenitors (LMPPs). CMPs will 
differentiate into erythrocytes and megakaryocytes, whereas LMPPs become common 
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lymphoid progenitors (CLPs) (Igarashi et al., 2002) which are able to differentiate into B 
and T lymphocytes as well as natural killer (NK) cells (Cobaleda and Busslinger, 2008; 
Kondo et al., 1997). 
In order to distinguish and identify all these types of cells, one can characterize them in 
terms of changes in their phenotype by using monoclonal antibodies that are reactive 
against various cell surface antigens expressed on particular lineages of terminally 
differentiated cells. For instance, to identify T-lineage cells, CD3, CD4 and CD8 are used, 
whereas B-lineage cells are identified with markers such as B220/CD45RA, CD19 and 
CD20. 
Overall, individual HSCs, but also more mature haematopoietic cells, can have many 
destinies: quiescence, apoptosis, migration and cell cycle in order to self-renew or to 
differentiate into their more mature progeny. These outcomes are influenced by 
combinations of both cell intrinsic and extrinsic factors, these last ones being specific of 
local microenvironments in which haematopoietic cells reside. A more complete 
knowledge of the effect of these factors on haematopoiesis may help understanding the 
pathology of certain hematologic diseases and may provide new and better therapies. 
 
1.1.3. B cell development 
To understand the role of the BM microenvironment in B-ALL, it is important to first 
understand how HSCs develop into mature B cells during normal haematopoiesis which 
involves the rearrangement and expression of immunoglobulin genes, crucial to make 
antibodies against a wide range of pathogens, which coincides with changes in the 
expression of cell-surface and intracellular molecules. 
With CLPs as intermediate, HSCs give rise to mature B cells that produce only one heavy 
chain (HC) and one light chain (LC) through the sequential differentiation of lymphoid 
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progenitor cells (LPCs). Once committed to the lymphoid lineage, further sequential 
differentiation steps, defined by the sequential rearrangement and expression of HC and 
LC immunoglobulin genes, lead to the progressive formation of early B cell precursors, 
immature B cells, and, after the mature B cell state, the terminally differentiated plasma 
cells (Figure 1). In order for this progression to occur, the cells have to activate in each 
stage the specific genetic program of the new intermediate stage alongside with the 
suppression of the genetic program of the previous stage. In the first step, CLPs 
differentiate into the early-B cells, a cellular state where the DJH rearrangements begin 
and B-lineage specific proteins such as VpreB and Igα (CD79a) are expressed. There 
are two main B cell precursors of immature cells: the pro-B cells and the cells that 
develop from these, the pre-B cells. Pro-B cells are progenitor cells with limited self-
renewal capacity. They express cell-surface CD19, CD34 and CD10 (Loken et al., 1987), 
but lack the expression of cytoplasmic or cell-surface µ heavy chains (HCs) and V-to-
DJH rearrangements occur (Davi et al., 1997), whereas pre-B cells besides expressing 
CD19 also express cytoplasmic µHCs, and variably express the pre-B cell receptor (pre-
BCR). The pre-BCR is a complex of proteins consisting of µHC, ψLC, and the Igα/Igβ 
signal transducing heterodimer (Benschop and Cambier, 1999) appearing at a critical 
initial checkpoint. Immature cells are no longer considered B cell precursors since they, 
in addition to expressing CD19, have on their cell-surface µHCs associated with κ or λ 
LCs, i.e. the B cell receptor (BCR). So, when B-lineage cells start expressing the BCR, 
they are no longer classified as B cell precursors (LeBien, 2000). Until this point, all 
development takes place in the BM and is independent of the presence of antigen. At 
this stage, immature B cells are selected for self-tolerance and ability to survive in the 
periphery. If they are able to do so, those B cells undergo further differentiation giving 
rise to naive mature B cells which express both IgG and IgM. These B cells circulate 
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through secondary lymphoid tissues where, if encountering their specific antigen, may 
be activated and are called mature cells. 
Figure 1 - Stages in human B-cell development (adapted from Nagasawa, 2006). 
 
Many external factors play a role in B cell lymphopoiesis. BMSC-derived molecules can 
stimulate survival/growth, differentiation, or chemotaxis in cells in different stages of 
differentiation. Such factors include Interleukin-7 (IL-7), CXC-chemokine ligand 12 
(CXCL12 or SDF1α and PBSF) which is a chemokine, a large family of structurally 
related chemoattractive cytokines, that primarily binds to CXC-chemokine receptor 4 
(CXCR4) as well as FLT3 ligand (FLT3L) (Nagasawa, 2006), and thymic stromal 
lymphopoietin (TSLP) (LeBien, 2000). The role of these and other stromal factors in B 
cell development will be discussed in more detail below. 
 
 
24 
 
1.1.4. Cellular niches in the Bone Marrow 
HSCs and haematopoietic cells are anatomically located and tightly regulated in the 
specialized microenvironment or niches in the BM (Fuchs et al., 2004). The 
microenvironment provides them with essential conditions for HSC maintenance by 
giving them cues to expand and differentiate, keeping a proper balance of the right 
amount of various immune cells, as well as creating a safe house that protects them from 
certain insults. 
The concept of haematopoietic microenvironments was first proposed forty years ago by 
Dr. John Trentin (Trentin, 1971). Trentin demonstrated that stromal cells had an active 
role in the regulation of the differentiation of HSCs into all blood cell lineage types and 
that marrow stroma is geographically segmented into microenvironments, each of which 
directs differentiation along a specific lineage. Schofield further expanded on these ideas 
and introduced the ‘niche’ concept to describe the specialized domains in the BM where 
HSCs reside and which contribute to the maintenance of their stemness (Schofield, 
1978). Moreover, he argued that once the HSCs leave the niche, they initiate maturation. 
Despite following studies (Dexter et al., 1973, 1977; Lichtman, 1981), the precise 
anatomical location of the BM niche and the exact identity of the cell(s) that the niche 
contained remained relatively unknown until the osteoblasts appeared as a critical 
component of the HSC niche (Calvi et al., 2003a, 2003b; Zhang et al., 2003), as well as 
the sinusoidal endothelial cells (Kiel et al., 2005). 
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Figure 2 - Schematic representation of the cellular niches for haematopoietic stem cells in the bone 
marrow (adapted from Doan and Chute, 2012) 
 
Nowadays it is accepted that HSCs are enriched within specialized areas of the BM 
microenvironment (Figure 2), namely the osteoblastic (or endosteal) niche (Nilsson et 
al., 2001; Zhang et al., 2003) and the vascular niche (Kiel et al., 2005), both of which are 
the major components responsible for supporting the maintenance, proliferation and 
differentiation of HSCs. Some authors also consider the existence of a third niche: the 
reticular niche (Purizaca et al., 2012). These reticular cells that have been found to be 
important for supporting haematopoiesis, might in fact be MSCs with the ability to 
differentiate towards the osteoblastic, adipocytic and chondrocytic lineage as well as 
expressing various factors important for supporting HSCs, such as CXCL12 and SCF 
(Frenette et al., 2013). However, since these reticular MSC-like cells surround the 
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vasculature and as the endosteal niche is highly vascularized, it is hard to distinguish 
between the endosteal, vascular and reticular niches. Altogether, this strengthens the 
concept that the BM niche should not be looked at as clear and defined structural 
compartments but rather viewed as an active interaction between different cellular 
components (Garrett and Emerson, 2009). Recently, also cells from the nervous system 
appeared as players in the BM niche, as glia cells maintain HSC hibernation by 
regulating the activation of latent TGF-β (Bruckner, 2011; Yamazaki et al., 2011). In 
addition the extracellular matrix (ECM) also plays essential roles. The ECM is a complex 
composition of collagens, proteoglycans, glycosaminoglycans, and glycoproteins such 
as fibronectin, osteopontin, laminins and thrombospondins (Klein, 1995). As such, HSC 
niches are quite complex, containing a broad range of BM cells which not only include 
bone lining cells (osteoblasts and osteoclasts), MSCs, sinusoidal endothelium and 
perivascular stromal cells, but also other cells such as adipocytes and mature immune 
cells. Elucidating the functions of these niches is crucial to understand the behaviour of 
HSC and hence exploit this knowledge for clinical applications. 
 
1.1.4.1. Stromal Bone Marrow Niche Cells Supporting HSCs 
The osteoblastic niche, thought to maintain HSC quiescence over the long term and 
located in the endosteum, contains both multi-cellular and acellular components. Growth 
factors and ECM constitute the acellular portion of BM. The main BM endosteal cells are 
multiple subsets of osteoblasts (OB) and mesenchymal progenitor cells (Nakamura et 
al., 2010). OBs, which differentiate from MSCs, lie at the inner surface of trabecular bone. 
Besides their role in providing mineralization during bone development and in replacing 
lost bone tissues in adults, since the early 1970s, studies have provided clues that OBs 
might also play an essential role in haematopoiesis (Gong, 1978; Lord and Hendry, 1972) 
and thereby play an important function as niche cells. In 2003, Li’s and Scaden’s groups 
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reported, in the same issue of the scientific journal Nature, experiments describing an 
important role for OBs in supporting HSCs in vivo (Calvi et al., 2003a; Zhang et al., 2003). 
Furthermore, defects in OB differentiation due to lack of Runx2, which plays a pivotal 
role in osteogenesis, lead to defective BM haematopoiesis (Deguchi et al., 1999; Wang 
et al., 2010). Endochondral ossification was demonstrated to be necessary for niche 
formation, as suppression of factors involved in the endochondral ossification inhibited 
niche generation (Chan et al., 2009). These studies indicate that osteoblastic cells 
represent a regulatory component of the BM microenvironment and suggested that HSC 
pool size is directly affecting OB numbers within the BM. OBs express factors such as 
cytokines, chemokines and adhesion molecules that have been specified for HSC 
regulation and adherence to OB. These include the ligand Angiopoetin-1 (Arai et al., 
2004), the non-canonical Wnt signalling (Sugimura et al., 2012) and thrombopoietin 
(Qian et al., 2007; Yoshihara et al., 2007) which play an essential role in maintaining 
HSCs in a quiescent state. CXCL12 is a chemokine abundantly expressed by OBs that 
has crucial roles in chemotaxis, homing, survival of HSC as well as in the retention of 
HSCs in the BM (Broxmeyer et al., 2005). Although it was initially believed that, when 
HSCs are associated with OBs they are in a quiescent state, more recent studies suggest 
that this role could rather be played by MSCs that also localize in the endosteal niche 
(see below). 
In addition to OBs, various cells that reside in the endosteal region of the BM are also 
able to either directly or indirectly regulate haematopoiesis. These include osteoclasts 
(Cho et al., 2010; Kollet et al., 2006; Lymperi et al., 2011; Mansour et al., 2012), 
macrophages (Christopher et al., 2011) and a specialized group of macrophages, the 
osteomacs (Winkler et al., 2010a). 
Evidence that HSCs may occupy multiple niches besides the osteoblastic niche has been 
accumulating, such as the vascular niche localized in the proximity of the sinusoidal 
vascular endothelium (Kiel et al., 2005). The vascular bed of the BM is predominantly 
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composed of sinusoids. As these vessels are thin, constituted by a single layer of 
endothelial cells (ECs), the marrow cavity is able to communicate with the blood 
circulation. In addition to ECs, this vascular niche comprises other types of cells (reticular 
cells, perivascular stromal cells, MSCs, and neurons) creating an elaborate niche that 
supports and regulates HSCs. The population of HSCs that locate in this niche has been 
suggested to be maintained over a shorter term, actively cycling, and replace circulating 
cells (Kopp et al., 2005; Winkler et al., 2010b). As such, the vascular niche would function 
as a gateway for HSC migration, circulation and anchoring (Doan and Chute, 2012; 
Sipkins et al., 2005a). However, a new view of the vascular niche has been proposed in 
which the existence of multiple vascular niches playing opposite roles in the maintenance 
of HSCs quiescence was demonstrated. According to this recent perspective, the 
sinusoidal vascular niche maintains cycling HSCs, whereas the quiescent HSCs are 
located in the arteriolar niche (Kunisaki et al., 2013). 
Moreover, the perivascular region also contains MSCs that are either identified as: 
CXCL-12-abundant reticular cells (CAR cells) or Nestin+ cells. CAR cells possess 
mesenchymal cell properties and are different from ECs and OBs (Greenbaum et al., 
2013). In the vascular niche, they are located closely to the sinusoids in the BM 
(Tokoyoda et al., 2004) but they can also be present in the endosteal niche (Sugiyama 
et al., 2006), where they also associate with HSCs and as such probably establish a 
bridge between these niches. Ablation of CAR cells in vivo decreased the ability of 
stromal cells to differentiate into adipogenic and osteogenic lineages and to produce 
SCF and CXCL12. It also results in a reduction in the number and size of HSCs (Omatsu 
et al., 2010). Frennete’s lab has demonstrated that MSCs can also be identified by Nestin 
expression since Nestin+ cells differentiate into mesenchymal lineages (osteoblastic, 
adipocytic and chondrocytic). These Nestin+ cells constitute a key component in the BM 
microenvironment, with their presence being necessary for homing and maintenance of 
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HSCs (Méndez-Ferrer et al., 2010; Muguruma et al., 2006). MSCs express molecules 
important for HSC control, including c-kit ligand, angiopoietin-1, IL-7 and osteopontin. 
The existence of MSCs leads to a convergent idea and perhaps a unifying niche theory 
regarding the cellular components of the HSC niche (Muguruma et al., 2006). Despite 
the vascular and osteoblastic niches can usually be physically and functionally 
distinguished, in some cases they can be overlapping. It was demonstrated that blood 
vessels may be present on the endosteal surfaces, establishing connections and 
regulating each other (Lo Celso et al., 2009; Kanczler and Oreffo, 2008; Xie et al., 2009). 
For instance, interaction between angiopoetin-1 produced by OBs and ECs expressing 
its receptor Tie-2 promotes angiogenesis and reduces vascular permeability (Fukuhara 
et al., 2008; Saharinen et al., 2008). 
In conclusion, the BM niche is an intricate microenvironment, which we are now little by 
little starting to understand. However, many questions remain unanswered. Considering 
the critical function of HSCs in the human body and its absolute dependence on 
communication with BM stromal cells, there is a huge need to fully understand the BM 
architecture and to address the molecular pathways by which these cells interact thereby 
regulating HSC state and function. 
 
1.1.4.2. Stromal BM Niche Cells Supporting B cell development 
Along with specific transcription factors (Ikaros, transcription factor E2A, early B cell 
factor and PAX5) which activities clearly determine B cell fate, it has long been known 
that microenvironmental cues, via surface bound as well as soluble molecules (Murti et 
al., 1996) are involved in regulating this differentiation process. I will therefore, after a 
brief introduction of the main factors involved in B cell development (IL-7, CXCL12 and 
galectin-1 or GAL1), describe the cells that express these factors: CXCL12-expressing 
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OBs, CXCL12-expressing MSCs, IL-7-expressing cells and GAL1-expressing cells. In 
addition, factors such as FLT3L, receptor activator of nuclear factor-κB ligand (RANKL), 
very-late antigen-4 (VLA-4) and vascular cell adhesion molecule-1 (VCAM) also appear 
to be crucial for B cell development (Jarvis et al., 1997; Nagasawa, 2006). 
In addition to being important for haematopoiesis in general, a crucial role of the 
CXCL12-CXCR4 axis in B cell development has been established. By generating mutant 
mice with a targeted disruption of the gene encoding CXCL12 it was demonstrated that 
this chemokine is essential for B cell lymphopoiesis (Nagasawa et al., 1996). Moreover, 
CXCL12 was identified as the first soluble factor essential for the earliest identifiable B 
cell precursor (Egawa et al., 2001) and inactivation of CXCR4 in B cells in mice proved 
that CXCR4 is required for retention of B cell precursors in the BM (Nie et al., 2004). 
ECs, OBs and MSCs are important stromal cell populations that have been suggested 
to express this chemokine. OBs appear to be able to support developmental transitions 
in B lymphopoiesis by locally secreting the stromal factors CXCL12 and IL-7, reviewed 
below, in addition to inductive signals that include VCAM-1–mediated adhesion. In 
accordance with this, selective elimination of OBs highly impaired both pre-pro-B and 
pro-B cells from BM (Zhu et al., 2007).  
Despite the existence of these various CXCL12 expressing cells, the specific role for 
each individual CXCL12 producing cell type in supporting HSC maintenance and 
retention, and in the generation of certain lymphoid progenitors only recently became 
elucidated. For this purpose, scientists selectively deleted CXCL12 from candidate niche 
cell populations known to express CXCL12. To target OBs, the Morrison’s lab used 
Col2.3-cre mice, and were able to reach the conclusion that CXCL12 impairment in OBs 
resulted in loss of B-lymphoid progenitors and B cell reconstitution (Ding and Morrison, 
2013). Deletion of CXCL12 in osterix-expressing cells, which included CAR cells and 
immature OBs, reduces the number of B lymphoid progenitors. This is in agreement with 
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previous studies in which CAR cells were found to be crucial for B lymphoid commitment 
(Omatsu et al., 2010). Deletion of CXCL12 from ECs, although neither depleting myeloid 
or lymphoid progenitors, did deplete HSCs and it was suggested to have a crucial role in 
HSC maintenance. The BM of Prx1-cre;Cxcl12fl/fl mice, having CXCL12 deletion in 
multipotent mesenchymal progenitors and perivascular stromal cells, had fewer 
committed B cell progenitors. In conclusion, both Morrison’s and Link’s groups 
demonstrated that HSCs are supported by a perivascular niche created by ECs and 
Lepr-cre or Prx1-cre cells. On the other hand, some early B-lymphoid progenitors occupy 
an endosteal niche comprised of OBs (Ding and Morrison, 2013) /osterix-expressing 
cells (Greenbaum et al., 2013), with commited B-lineage progenitors depending on Prx1-
cre cells that create a distinct perivascular niche. 
In addition to CXCL12-expressing cells, several other cell types have been implicated in 
providing the specific factors necessary for B cell development (Figure 3).  
 
Figure 3 - Possible cellular niches involved in B-cell development and model of the movement of 
multipotent hematopoietic progenitors, B cells and their precursors in the bone marrow, throughout 
development (adapted from Nagasawa, 2006) 
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IL-7 was the first identified environmental factor to be able to induce proliferation of B 
cell precursors (Namen et al., 1988), having a unique and nonredundant role in the 
formation of both B and T cell lineages (von Freeden-Jeffry et al., 1995; Peschon et al., 
1994). The receptor of IL-7 includes two subunits: the IL-7Rα chain, shared with TSLP, 
and the cytokine-receptor common γ chain (γc). IL-7 has been shown to be essential at 
the pro-B cell stage as mice deficient in either IL-7 or IL-7Rα had normal numbers of pre-
pro-B cells but a significant impairment in the number of pro-B cells, pre-B cells and B 
cells in a more differentiated stage (von Freeden-Jeffry et al., 1995; Peschon et al., 
1994). Contradicting these results, by the analysis of IL-7-deficient mice, Dias et al 
demonstrated that IL-7 appears to have an important role as early as the CLP stage 
during B cell development (Dias et al., 2005). However, it appears that in humans there 
is no such dependency on IL-7 as people who lack the expression of IL-7Rα don’t have 
impaired B cell development (Puel et al., 1998). 
A population of fibroblast-like cells scattered throughout the BM expresses IL-7, along 
with VCAM-1 (Funk et al., 1995; Tokoyoda et al., 2004). IL-7 production by stromal cells 
is induced by the IL-7-dependent B cells (Sudo et al., 1989). The niche provided by these 
cells is thought to contribute to clonal expansion of B cell precursors and also plays a 
role in the earliest stages of B cell development. Even though both IL-7 and CXCL12 
play crucial roles in B cell development and frequently may have additive or synergistic 
functions, B cell precursors  are present distinct stromal-cell subsets as they are located 
differently in the BM and CAR cells don’t express IL-7 (Tokoyoda et al., 2004). 
Recently, a specific stromal cell microenvironment was identified for pre-BII cells 
(Mourcin et al., 2011), one subtype of human pre-B cells that express a functional pre-
BCR and, in opposition to pre-BI cell which are large proliferating cells, are small 
postmitotic cells (Ghia et al., 1996). This niche is comprised of GAL1-expressing stromal 
cells. Mourcin and colleagues provided evidence supporting early B cell migration from 
IL-7+ to GAL1+ niches during their development. 
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In summary, the stage-specific cellular niches, which secrete factors that regulate the 
mobilization and stromal cell interactions of haematopoietic precursors, are required 
throughout the development of B cells. B cell precursors and plasma cells are localized 
in their specific niches, migrating between them as development proceeds (Nagasawa, 
2006). Early B cell precursors require CXCL12 and IL-7 (Egawa et al., 2001; von 
Freeden-Jeffry et al., 1995; Nagasawa, 2006) with the cellular candidates for CXCL12 
expression being CAR cells and/or OBs (Greenbaum et al., 2013). Pre-pro-B cells 
require CXCL12 associating with CAR cells close to the vasculature. As IL-7 is essential 
for pro-B cells/pre-BI cells, they migrate from CAR cells in direction to IL-7 expressing 
cells. These cells may induce an expansion division, considering the characteristics of 
pro-B cells/pre-BI cells (mitotically active and requirement of IL-7 for proliferation) (von 
Freeden-Jeffry et al., 1995). At the next step, the pre-BII cell stage, the pre-BCR is 
formed and expressed at the surface. At this stage, cells leave IL-7 expressing cells and 
move to the GAL1+ niche during their differentiation (Mourcin et al., 2011). Newly 
generated immature B cells which express IgM leave the BM and enter the blood to 
reach the spleen. There they may encounter their specific antigen leading to maturation 
into peripheral mature B cells. End-state cells reside once again in close proximity of 
CAR cells in the BM. The majority of long-lived plasma cells reside in the BM, homing 
that fails upon deletion of CXCR4 (Tokoyoda et al., 2004). CXCL12 likely supports 
homing thereby contributing to the survival of plasma cells as they consequently localize 
in the niches of BM. 
 
1.1.5. Acute lymphoblastic Leukaemia 
Uncontrolled malignant growth of blood cells is characteristic of leukaemia, which 
comprises two main classes: acute, commonly found in children, being its incidence 
peaks between 2 and 5 years of age, and chronic. The major difference between them 
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is that in the acute form there is a rapid accumulation of malignant cells in the BM and 
bloodstream due to loss of regulation of haematopoiesis at the very initial steps, while in 
the chronic form the progression is slower and malignant cells are relatively differentiated 
and potentially not fully functional. Acute leukaemias can be divided into lymphoblastic 
(ALL) and myeloid (AML) cell malignancies, according to the affected cell lineage. ALL 
is a malignant neoplasm of the lymphocyte precursor cells or lymphoblasts, i.e., of the 
cells having lymphoid origin. These leukemic lymphoblasts have an exacerbated and 
uncontrolled growth that results in the clonal accumulation of immature blood cells in the 
BM. These abnormal cells are arrested in the lymphoblast stage of the normal maturation 
pathway so they are unable to mount a normal immune response. They may also lead 
to an impaired production of normal BM cells since normal haematopoiesis is 
suppressed, consequently depleting the number of circulating erythrocytes, platelets and 
leukocytes other than lymphocytes that may cause anaemia, thrombocytopenia or 
neutropenia, respectively. The most common symptoms are fatigue and spontaneous 
bleeding, and often present, malaise, lethargy, weight loss, fevers as well as bone and 
joint pain. ALL represents approximately less than 1% of adult cancers, but accounts for 
25% of all childhood cancers and 75% to 85% of all childhood leukaemias (Miller et al., 
1995; Perez-Saldivar et al., 2011). Despite less than half of all adult leukaemia patients 
survive 5 years after diagnosis, almost two-thirds of all adult ALL cases survive at least 
5 years after diagnosis. In children the survival is much better with more than three-
quarters of all children with leukaemias and more than four-fifths of ALL cases surviving 
at least 5 years past diagnosis (Ries et al., 2006), now approaching 90% of survival 
(Hunger et al., 2012). 
In terms of aetiology, the pathology of ALL is associated with genetic abnormalities in 
more than 75% of the cases (Pui et al., 2008) that can be chromosomal translocations, 
chromosome copy number alterations or gene-specific mutations. In most cases, these 
abnormalities are acquired rather than inherited. A hallmark of acute leukaemias is the 
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presence of aberrant fusion genes that, even though alone are unable to induce the 
disease, increase the predisposition of the carriers to the disease. The disease onset 
may also require acquisition of additional genetic or epigenetic alterations. 
Translocations are especially common in childhood ALL and the ones frequently found 
in ALL cases include the TEL-AML1 translocation - the most common reciprocal 
translocation which occurs in about 25% of cases (Shurtleff et al., 1995), MLL 
translocations, MLL-AF4gene fusion, t(9,11)(p22;q23) and t(11, 19), and CDK6-MLL. 
Modifications in the function of certain transcription factors including Ikaros, E2A, EBF 
and Pax5 are thought to contribute as well to leukaemogenesis (Pérez-Vera et al., 2011). 
Furthermore, physical and chemical risk factors may also make a contribution to this 
complex and heterogeneous disease. 
Despite the advances of the therapeutic options and the prolonged survival in recent 
years thanks to them, devastating developmental effects may arise due to high dose 
chemotherapy as well as an increase on the risk of secondary cancers (Haddy et al., 
2009).  Moreover, ALL is still far from being eradicated because of the recurrence after 
the treatment in many cases (Yang et al., 2008). The BM niche is thought be a critical 
component in relapse. 
 
1.1.5.1. B Acute Lymphoblastic Leukaemia 
From the ALL-cases in children, around 80-85% are B- cell ALL (B-ALL) (Perez-Saldivar 
et al., 2011). Also in adults, B-lineage leukaemias dominate within the lymphoid 
leukaemia patient group (>75%) (Hjalgrim et al., 2003). B-ALL is characterized by 
malignant and uncontrolled growth of B-lymphoid precursor cells in BM. The 
accumulation of blast B cells leads to a decrease in normal haematopoiesis besides 
invasion of extramedullary regions by these cells. 
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Being a subtype of ALL, a set of gene fusions created by chromosomal translocations 
are involved in the genesis of B-ALL: TEL-AML1, MLL rearrangements, BCR-ABL and 
E2A-PBX1. The frequency of chromosome translocations varies between children and 
adults. TEL-AML+ leukaemias are most prevalent in children (22% vs. 2% in adults), 
whereas BCR-ABL+ are most prevalent in adults (25% vs. 3% in children). Although it is 
difficult to determine in which stage of the B-lymphoid lineage differentiation process the 
translocation occurred, considering their known biological properties some origins have 
been proposed: if occurring in an early progenitor, the BCR-ABL and MLL translocations 
may be involved, while TEL-AML1- and E2A-PBX1 appear in a more advanced state of 
differentiation (Cobaleda and Sanchez-Garcia, 2009). These primary oncogenic events 
seem to be insufficient to cause a completely malignant cell, a process which requires 
other supportive changes. Somatic mutations leading to the constitutive activation of 
certain signalling pathways contribute to proliferation and survival of B lymphoblasts, 
including abnormal IL-7 and TSLP receptors that are constitutively activated (Tal et al., 
2013). Besides this, as a cancer supportive effect, interaction of B precursor cells with 
cells in their surroundings influences leukaemia progression. 
 
1.1.6. Contribution of the bone microenvironment to leukaemia 
The BM niches are also important in malignancy, as it has been established that 
alterations in cell composition and function in the microenvironment regulates stem cell 
activity. BM is the most common site of disease in hematologic malignancies, as its 
microenvironment is a fertile location for leukemic cells growth and tumour dormancy, 
i.e. cells that are not proliferative but can later enter a proliferative state. This happens 
mostly because the BM provides cues which support leukemic cells homing, adhesion 
and survival. When comparing BM-derived MSCs from normal and leukemic patients, B-
ALL cells survive more and better in vitro when placed in the leukemic environment 
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(Nwabo Kamdje et al., 2011; Rodríguez-Pardo and Vernot, 2013). Of note, the influence 
appears to be in both directions, with cells from different types of leukemia creating 
abnormal niches and altering stromal cell function and these stromal cells in return 
contributing to the survival and proliferation of tumour cells (Ayala et al., 2009). Some 
hypotheses have been proposed regarding the mechanisms by which the niche 
contributes to leukemogenesis (Purizaca et al., 2012): (1) competition of leukemic cells 
for the BM niche leading to dysfunctional microenvironments for normal HSCs (Colmone 
and Sipkins, 2008); (2) the capability of certain stromal cells to facilitate tumour 
progression and/or (3) disruption of cross-talk between HSC and microenvironment. The 
group of Emmanuelle Passegué recently obtained proof for these concepts in a mouse 
model for chronic myeloid leukaemia (CML) (Schepers et al., 2013). This study described 
in detail the cellular and molecular cross-talk between leukemic cells and the 
microenvironment that result in a self-reinforcing leukemic niche. In addition, interaction 
of leukaemia cells with the BM stroma has been proposed as a mechanism for 
chemotherapy resistance (Ayala et al., 2009; Azab et al., 2009; Mudry et al., 2000; Tesfai 
et al., 2012), as stromal interactions protect leukemic cells from the effects of 
chemotherapeutic agents, and cancer recurrence by up-regulating anti-apoptotic 
proteins (Frolova et al., 2012). 
In particular, a number of alterations have been suggested to occur in the BM 
microenvironment in B-ALL and other types of leukemia, a few of which I briefly mention 
here and others that I will describe in more detail in the following section. Leukaemia-
associated genetic aberrations in MSCs have been detected which indicates that 
different cell types are involved in the pathogenesis and pathophysiology of leukaemia 
and suggests that MSC may be involved in the generation of relapse (Menendez et al., 
2009; Shalapour et al., 2010). Deleting Dicer1, an RNase III enzyme, from mouse 
osteoprogenitors causes haematopoietic malignancies (Raaijmakers et al., 2010), 
emphasizing the relevance of external cues provided by stromal cells. 
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Neoangiogenesis, the formation of new blood vessels, is a hallmark of cancer, and 
contributes contributing to cancer progression. Even though ALL is not a solid 
malignancy, various proangiogenic factors are abnormally expressed in B-ALL patients 
and angiogenesis in ALL is of utmost importance in leukemogenesis, leukemic 
progression and treatment (Aref et al., 2007; Perez-Atayde et al., 1997; Veiga et al., 
2006; Zhou et al., 2005). B-ALL cells thus seem to stimulate ECs, and these in a 
reciprocate manner induce B-ALL survival. 
In addition to genetic modifications and increased vascularization, over-activation of 
some signalling pathways due to intrinsic activation of these pathways by genetic 
changes or extrinsic factors may promote leukemogenesis (Chung et al., 2002). 
Alterations in ECM components may also lead to haematological malignancies. For 
instance, reticulin fiber density was shown to be a useful prognostic marker in pediatric 
ALL (Noren-Nystrom et al., 2008). Moreover, in the ALL malignant niche there is a 
prevalence of pro-inflamatory cytokines: TNF-α and IL-6, thus creating an abnormally 
inflammatory niche (Espinoza-Hernandez et al., 2001). 
Recently, another type of interaction between leukemic cells and the microenvironment 
was identified. AML cells were shown to secrete core histones associated with 
fragmented DNA which can enter the nuclei of BM cells, integrate into host cell DNA and 
lead to death of stromal cells (Dvořáková et al., 2012). 
All these further stress the importance of the BM stroma in leukaemia.  
 
1.2. Role of stromal-derived molecules in B-ALL growth 
As discussed above, the BM niche is a main contributor to cancer progression and 
resistance to treatment. The growth and survival of leukemic B cell progenitors is 
dependent on intimate contact with BM stromal layers (Kumagai et al., 1996; Manabe et 
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al., 1992). In this section I will focus on and describe how BM-derived stromal factors 
may lead to B-ALL. I will give special attention to VCAM-1, CXCL12 and IL-7 which have 
been demonstrated to be critically involved in leukaemia-microenvironment cross-talk. 
All the interactions described here are summarized in Figure 4. 
 
Figure 4 - B-ALL microenvironment: interactions between stromal cells in the malignant niche and 
leukemic cells. 
 
1.2.1. In vitro murine/human studies 
Following treatment of B-ALL, the origin of recurring malignant cells appears to be the 
BM. Consequently, it has been proposed that the BM creates niches that protect 
leukemic cells from apoptosis. Research has been performed trying to understand the 
biologic architecture of this host microenvironment since this has huge implications for 
treating tumors. The BM niche has also been implicated in B-ALL growth. One approach 
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that may facilitate identification of BM stromal cell factors essential for both survival and 
expansion of human leukemic B cell precursors is the in vitro co-culture of human BM 
stromal cells with leukemic cells. First of all, in vitro studies have shown that culturing 
primary B-ALL lymphoblasts in the presence of B-ALL-patient derived BM MSCs leads 
to changes in the cytokine expression of the leukemic cells, which may explain BM MSCs 
support of B-ALL cells (Wu et al., 2005) and close association of ALL to BM niche cells 
results in an important ALL survival effect in vitro (Murti et al., 1996). Nevertheless, this 
BM microenvironment dependency may vary depending on the leukemic subclone as it 
was observed that distinct B-ALL subclones present different requirements from the BM 
niche (Shah et al., 2001).  
By monitoring apoptosis, direct contact with stroma has been established as a survival 
requirement for normal B lymphoblasts (Kumagai et al., 1996; Manabe et al., 1994). A 
crucial adhesion pathway through which precursor-B ALL cells bind to BM stroma has 
been demonstrated to be via the beta1 integrins VLA-4 and VLA-5 and this adhesion is 
partly mediated by VCAM-1 on stromal cells (Makrynikola and Bradstock, 1993; Miyake 
et al., 1992). BM stromal cells constitutively expressing VCAM-1 increase the survival of 
B-ALL cells (Hall et al., 2004a). Notch signalling also plays a role in the survival of B-ALL 
cells, as Notch neutralizing antibodies decreased the survival of primary B-ALL cells 
when co-cultured in the presence of BM-derived MSCs (Nwabo Kamdje et al., 2011). 
Furthermore, both pathways were shown to be important in conferring resistance to 
certain chemotherapies (Hall et al., 2004a; Nwajei and Konopleva, 2013). 
Stromal cells secrete selective chemotactic factors which attract and concentrate 
leukaemia cells in their selective local microenvironment, being therefore important for 
both migration and homing. As mentioned above, CXCL12 was demonstrated to be a 
potent chemokine for normal B precursor cells. Moreover, CXCL12 has also been 
implicated in malignant B cell development as Bradstock and colleagues showed 
precursor-B ALL cells preferentially localize close to the BM-derived cells in vitro in a 
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process dependent on CXCL12 binding to its receptor CXCR4 on leukemic cells 
(Bradstock et al., 2000).  
It has long been known that IL-7 is able to induce a proliferative response in both B cell 
precursor-acute lymphoblastic leukaemia and immature T-ALL cells (Eder et al., 1990; 
Touw et al., 1990). When studying the mechanism of action of an mTOR inhibitor in 
malignant progenitor B cells, IL-7 played a critical role in stimulating the proliferation of 
leukemic cells (Brown et al., 2003). Findings further support a role for the IL-7/IL-7R axis 
in B cell oncogenesis given the upregulation of IL-7 receptor (IL-7Rα) by B-ALL cells 
(Sasson et al., 2010). This suggests an increased activation of this pathway in B cells in 
the BM niche. On the other hand, overactivation of IL-7 signalling pathway may occur 
due to gain-of-function mutations in IL-7Rα (Shochat et al., 2011). An elegant experiment 
using primary T-ALL cells cultured in vitro with either human BM stromal or a murine 
fibroblast-like cell line of BM stromal origin, resulted in enhanced survival of T-ALL cells 
mediated by BM stroma in both cases and requiring the IL-7/IL-7R interaction. When 
blocking IL-7/IL-7R, the survival was only partially inhibited, suggesting the existence of 
cooperation by other mechanisms (Scupoli et al., 2007). In addition to a supportive effect 
mediated by IL-7 as mentioned above, IL-7 has also been shown to enhance the survival 
mediated by BM stroma in B-ALL cells when in the presence of CXCL12 and IL-3 (Juarez 
et al., 2007a). 
TSLP, not only shares one of its receptor’s chains, IL-7Rα, with IL-7, but also has similar 
biological functions to IL-7 (Sims et al., 2000). Brown and colleagues have shown that, 
similar to IL-7, TSLP stimulates B-ALL cell proliferation, in a dose-dependent manner 
(Brown et al., 2007). Furthermore, TSLP contributed to chemoresistance by decreasing 
the growth inhibition and pro-apoptotic effect of rapamycin. Since in this study they 
treated the cells directly with TSLP, it remains unknown whether BMSCs could be a 
potential source of this factor. 
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Co-culture of patient-derived B-ALL blasts with B-ALL BM stromal cells leads to up-
regulation of a group of BM stromal genes encoding secreted proteins, including CCL2 
and IL-8/CXCL8 which were able to increase the adhesion of ALL cells to BM stromal 
cells and to promote survival and proliferation of BM stromal cells (de Vasconcellos et 
al., 2011). Therefore this may represent a molecular mechanism by which tumor cells 
contribute to the establishment of a malignant BM microenvironment. 
Using an animal model of both obesity and leukaemia, a link between obesity and 
leukemogenesis. Leptin, IL-6 and insulin were in higher levels in obese mice when 
compared to control mice and may accelerate the progression of B-ALL (Yun et al., 
2010). Leptin is of particular interest since B-ALL lymphoblasts may express leptin 
receptors, thus suggesting a possible involvement of adipocytes in leukemogenesis.   
Additional factors that support B-ALL cell growth are factors such as FLT3 ligand (Eder 
et al., 1996), Interleukin-3 (IL-3) and low-molecular-weight B cell growth factor (Duyn et 
al., 1999; Wormann et al., 1987), that all stimulate B-ALL cell growth in vitro. 
In conclusion, leukemic cells are highly reliant on the BM microenvironment for their 
survival and proliferation in vitro. Many cytokines, chemokines and other stromal cell 
derived factors have been examined for their contribution, but none is able to fully 
substitute BM stromal support, suggesting that combinations and synergistic interactions 
of these and other factors still not identified may be required for optimal in vitro growth 
and survival. Actually, Juarez and colleagues have demonstrated that there is a complex 
pattern of interaction between the signalling pathways initiated by CXCL12, IL-7 and IL-
3, with additive or synergistic interactions between CXCL12 and IL-7 or IL-3 which 
promote the proliferation of ALL cells in some cases (Juarez et al., 2007a), highlighting 
the necessity to study such complex interactions in further detail. 
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1.2.2. In vivo mouse studies 
Although interaction of B-ALL cells with the BM microenvironment has been extensively 
studied in vitro thereby shedding some light on BM biology and its role in leukemic cell 
homing and progression, in vitro techniques are quite limited in their ability to mimic the 
whole physiology of BM architecture. In vivo studies appear as better models to study 
the role of BM in leukemogenesis. In this section, I will review various animal models that 
have been used to study B-ALL. Most in vivo studies performed so far are based on 
transplantation of cell lines into immunodeficient mice and/or rely on genetically 
manipulated mice, in which the expression of a certain gene was ablated or increased. 
In vivo studies have confirmed the role that adhesion molecules such as integrins, VLA4 
being the most prevalent one, play in the homing of B-ALL cells. B-ALL cells lacking 
expression of VLA-4 were generated from the pre-B-ALL cells line NALM-6 and 
intravenously injected into immunodeficient mice. In comparison to mice injected with 
wild-type NALM-6 cells, mice injected with NALM-6 cells lacking expression of VLA-4 
had a prolonged survival and leukemic cells engrafted less efficiently in the mice (Filshie 
et al., 1998). In another study, there was a significant decrease in the homing of B-ALL 
cells in the BM of NOD/SCID mice when these were treated with neutralizing VLA4 
antibodies (Spiegel et al., 2004). Recently, it was demonstrated that pharmacological 
blocking of integrin alpha4, a constituent of VLA-4, in mice as well as deletion of integrin 
alpha4 in mice make B-ALL cells more sensitive to chemotherapy (Hsieh et al., 2013). 
Using dynamic in vivo confocal imaging, Sipkins and colleagues revealed that NALM-6 
cells specifically localized in a unique and spatially-restricted vascular domain which are 
CXCL12 and E-selectin positive. They demonstrated that the BM expressed specific 
vascular cell surface adhesion molecules and chemoattractants necessary for malignant 
cell homing to these areas, as when inhibiting CXCL12 signalling the homing was 
decreased by almost 80% (Sipkins et al., 2005a). This was in accordance to previous 
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studies in which it had been demonstrated that CXCR4 and CXCL12 play a significant 
role in the in vivo engraftment and homing of NALM-6 cells to the BM of NOD/SCID mice 
(Shen et al., 2001). Moreover, others have used CXCR4 antagonists in NOD/SCID mice 
administered with human leukemic cells showing that this resulted in the inhibition of the 
growth and dissemination of patient ALL cells (Juarez et al., 2009). 
Mice expressing IL-7 under control of an immunoglobulin heavy chain promoter and 
enhancer, which leads to overexpression of IL-7 in hematopoietic cells in the BM, lymph 
nodes, spleen, thymus and skin, developed both B and T lymphomas (Rich et al., 1993). 
Although use of mice overexpressing IL-7 in hematopoietic cells allows the study of the 
role of IL-7 as an oncogene, i.e. as an initial promoter of leukaemia, this does not allow 
studying whether stromal cell-derived IL-7 is also involved in the support of in vivo growth 
of leukemic cells. Other studies that report on the role of IL-7 in vivo focus mainly on T-
ALL and not B-ALL (Zenatti et al., 2011). IL7R mutations promote tumor formation in T-
ALL. In another study, in which the aim was to directly assess the role of stromal cell-
derived IL-7 in leukaemia growth, the ability of human T-ALL cell lines to engraft and 
expand in an immunodeficent mouse was significantly reduced if the mouse that lacked 
IL-7 (Silva et al., 2011). 
Leukemic dormant cells are able to evade death from cytotoxic chemotherapy since this 
mostly targets cells in proliferation. Boyerinas et al. have provided proof that osteopontin, 
a protein secreted by OBs, anchors NALM-6 cells and regulates their dormancy in 
xenografted mice. Targeting this interaction therefore increased the sensitivity of 
leukemic cells to chemotherapy (Boyerinas et al., 2013). Once again, the importance of 
the communication between tumor cells and the microenvironment was highlighted, 
suggesting that targeting this interaction may improve the efficacy of B-ALL treatment. 
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1.3. Microenvironmental targets for B-ALL treatment 
As described previously, evidence indicates that the BM microenvironment plays a 
crucial role in the survival and proliferation of B-ALL cells, supporting their growth. 
Because of the sanctuary for leukemic cells that the (malignant) niche creates, stroma-
derived factors are thought to contribute to the decrease in the sensitivity, and thus 
efficacy of chemotherapy, as well as to the relapse of the disease. Consequently, the 
disruption of such communication appears as a promising approach to treat cancer in 
combination with chemotherapy and prevent its relapse. A scarce number of patients is 
able to survive long-term due to leukaemia recurrence (Pui and Evans, 2006; Stock, 
2010). Some molecular pathways have been suggested to be critical for the interactions 
between leukemic cells and the BM niche thus emerging as possible therapeutical 
targets. 
Currently, the main approaches consist of directly inhibiting the molecules which are 
responsible for the activation of the proliferative/anti-apoptotic pathways or, as 
alternative, targeting the molecules that contribute to the homing process. Regarding the 
first approach which is directed at the proliferative compartment, the most common 
targets are specific signalling pathways, such the PI3K/Akt, JAK/STAT and Notch1 
pathways, that are key in regulating B-ALL growth and survival, and inhibiting the activity 
of anti-apoptotic proteins (Brown et al., 2008; Fowler and Oki, 2013; Konopleva et al., 
2009). B-ALL studies are still in a preclinical stage but presenting interesting results. For 
instance, Akt pathway appears to be a promising target as its activation has been 
demonstrated to play an important role in chemotherapy, and is associated with poor 
prognosis and relapse (Morishita et al., 2012). Other targets such as angiogenesis 
inhibitors are also being studied (Konopleva et al., 2009).  
In order for leukemic cells to successfully home to the BM microenvironment, they have 
to go through three steps: migration, adhesion and secretion of metalloproteinases to 
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clear their path so that they are able to reach their destination. Therefore, efficient 
targeting of these stages has appeared as an exciting option for therapy, either alone or 
in combination with the above mentioned approaches. Given the large amount of 
evidence demonstrating its crucial effect in the attraction and homing of leukemic cells, 
targeting the CXCL12/CXCR4 axis by CXCR4 antagonists has been particularly well 
studied. The importance of leukemic migration has been confirmed since as a result of 
CXCR4 inhibition, human B-ALL cells were more responsive to chemotherapy in NSG 
mice (Yu et al., 2011). Furthermore, the combination of CXCR4 antagonists with the 
conventional chemotherapy drugs improved the survival and reduced the presence of 
human pre-B-ALL cells in NSG mice (Parameswaran et al., 2011). In addition to 
migration, adhesion molecules are crucial. Studies focusing on interfering with adhesion 
molecules function, specially targeting integrins (VLA4/VCAM-1 interaction), are being 
developed (Konopleva et al., 2009).  
Finally, other strategies to modulate the BM niche have been developed. A particular 
attention has been given to hypoxia mediators because long-term HSCs may be located 
in regions in the BM with lower oxygen content (Parmar et al., 2007) and because 
hypoxia stimulates angiogenesis. Importantly, in pre-B ALL co-cultured with BM-derived 
MSCs HIF-1α-mediated signalling has also been demonstrated to be part of the 
mechanism of chemoresistance in hypoxic conditions (Frolova et al., 2012). 
In addition to these, many other factors might still be unidentified and/or their complete 
function remains unknown. The identification of the synergistic and additive interactions 
between them is imperative in order to be able to fully manipulate the BM 
microenvironment and thereby improve B-ALL therapy.  
Despite the approaches used so far, the role of various stromal factors in B-ALL growth 
and survival remains not fully known, mainly due to the lack of appropriate models that 
simulate human haematopoiesis and its interaction with the BM in an in vivo setting. 
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However, with recent advances in xenograft models we start to get closer to being able 
to simulate the human BM niche and to study the role of stromal cell-derived factors in 
human B-ALL growth and survival. The novel and sophisticated animal models will play 
a crucial role as they are becoming closer to simulating the human BM niche. 
 
1.4. Xenograft models of ALL 
In vivo disease models present some advantages in comparison to in vitro models: they 
are more representative of the physiological human situation and increase our 
knowledge in a clinically more relevant setting. Regarding haematological diseases, the 
preclinical models most commonly used are the genetically engineered mouse models 
and human tumour xenografts in immunocompromised mice. In spite of all the 
development that has been put into animal models of ALL, progress has been partially 
limited due to lack of knowledge of the microenvironmental factors needed for successful 
engraftment. In addition, we must be cautious when interpreting the results obtained as 
whereas the leukemic cells in these xenograft models are human, the microenvironment 
is murine thereby not fully mirroring the human/patient condition (Lee et al., 2007). 
In this section I will briefly mention the various xenograft models that have thus far been 
used for studying ALL, giving thereafter emphasis on recently developed in vivo 
xenograft models that have the potential to really move forward the study of the role of 
the BM microenvironment in human B-ALL growth. 
 
1.4.1. Human tumour xenografts models 
Xenograft models show a high degree of consistency and predictability for disease 
development, having provided an important tool to study various aspects of leukaemia 
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biology. Furthermore, if properly used and interpreted they can be quite useful. However, 
it is always good to consider that they probably don’t completely predict the behaviour of 
the disease in humans and the conditions for engraftment in the host may exert a distinct 
pressure for selection of subclones. Consequently, the results obtained may vary with 
the experimental setup. 
Xenograft leukemia models can be divided in two main subtypes: ectopic or 
subcutaneous models and orthotopic models. The first one is unable to represent the 
physiology of the disease due to its subcutaneous localization (Kerbel, 2003). When the 
implanted cells are grown in the tissue of the host where they normally reside, the model 
is known as orthotopic. Clinically relevant targets are better represented by this tumour 
system as it better simulates the morphology, microenvironment, growth and metastatic 
patterns of the human disease (Bibby, 2004). 
Xenotransplantation of human tumour explants and cell lines has been made possible 
with the development of immunocompromised animals. Immunodeficient mice have 
been generated aiming at creating animals with the least residual immunity. Athymic 
mice, which inherit an autosomal recessive gene (nu/nu) and lack functional T cells, were 
the first type of such animals used in xenograft experiments. When chronic myelogenous 
leukemic (CML) cells were transplanted into these mice, they developed tumours 
resembling those of the patient (Lozzio et al., 1976). The engraftment of leukaemia cells 
improved with the development of the severe combined immunodeficient (SCID) mouse 
(Bosma et al., 1983; McCune et al., 1988) and the bg/nu/xid (BNX) mouse (Kamel-Reid 
and Dick, 1988). The BNX mouse model has three crucial mutations: the nude(nu) that 
leaves the animal athymic, the beige(bg) which reduces the number of NK cells and the 
xid that limits the number of lymphokine activated killer cells (LAK). In addition to the 
BNX mouse, NOD (non obese diabetic)/SCID mice are the most common models, which 
has proven to be an accurate and reliable model to study ALL (Baersch et al., 1997; Lock 
et al., 2002). Even so, there were still some barriers that limited engraftment of leukemic 
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cells. Taking that into consideration, McKenzie et al. improved it by using an anti-CD122 
antibody (McKenzie et al., 2005). This antibody targets the interleukin-2 receptor beta 
(IL-2Rβ) therefore affecting many haematopoietic populations including NK cells and 
macrophages (Shultz et al., 2003). The levels of engraftment were higher when anti-
CD122 antibody was injected in NOD (Shultz et al., 2003) and NOD/SCID mice 
(McKenzie et al., 2005). Other strains have been developed with impaired innate 
immunity, stressing the importance of lack of macrophage activity, for human 
engraftement as well as absent NK activity. This was achieved by introducing into 
NOD/SCID mice additional defects for instance the lack of the the common cytokine 
receptor γ chain (γc) (i.e. creating the NSG strain) (Ohbo et al., 1996; Shultz et al., 2005). 
Another mouse strain frequently used is a genetic cross of a recombinase activating 
gene 2 (RAG2)-deficient strain, which lacks all T, B and NK cells, with mice deficient for 
γc (RAG2-/-γc-/-). 
Besides the mouse strain used, the biology and clinical course of leukaemia in the 
xenograft model also depends on many other factors that may increase or decrease the 
success of the engraftment, including: (a) the source and processing of leukaemia cells; 
(b) the route of administration and conditioning of the host; and (c) the method selected 
to characterize the manifestation of leukaemia (Meyer and Debatin, 2011). Furthermore, 
the environment that the leukemic cells encounter in the recipient affects their survival 
and homing not only because of the potential presence of residual immunity but also due 
to cross-species reactivity of homing molecules and growth factors (Manz, 2007). Aiming 
at overcoming this, Rongvaux et al. developed a humanized transgenic mouse model in 
which the gene encoding mouse thrombopoietin (TPO), which has been demonstrated 
to be an essential cytokine in the maintenance and self-renewal of HSCs, was replaces 
by its human form in mice with a Rag2−/−γc−/− background. This humanized model 
represents a valuable model to study human haematopoiesis in vivo as it has higher 
levels of human engraftment in the BM of the hosts as compared to regular Rag2−/−γc−/−  
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mice (Rongvaux et al., 2011). Others have also reported that  improved engraftment of 
AML xenografts engraft significantly better in β2-microglobulin-deficient NOD/SCID and 
NOD/SCID mice which were transgenic for the human growth factors genes Steel factor 
(SF), IL-3 and granulocyte macrophage-colony-stimulating factor, which are elevated in 
the serum of these mice (Feuring-Buske et al., 2003). 
In summary, by increased immunodeficiency and generation of transgenic mice 
expressing human cytokines, the models have obtained a better ability to engraft human 
cells. Nonetheless, for a long time human cancer xenografts have not been simulating 
the appropriate cancer stroma environment in immune-compromised mice. 
Consequently, they may be more sensitive to drug treatment (Olive et al., 2009) and may 
not fully mirror inflammatory responses (Quintana et al., 2008). Trying to overcome this, 
xenograft approaches are currently under study in order to better model the tumour 
microenvironment. These methods include the transplantation of human leukemic cells 
into mice that have been “humanized” by the incorporation of implants that simulate the 
human BM microenvironment, as will be discussed below. 
 
1.4.1.1. In vivo models to study the BM microenvironment 
One of the major limitations of the previously mentioned xenograft models is that the 
human cells engraft in a murine BM environment that may not reflect the interactions 
between the hematopoietic cells and the BM microenvironment in humans. Trying to 
overcome this issue, MSCs have been used as scaffolds for the formation of humanized 
stem cell niches in mice as they demonstrate both positive and negative regulatory 
effects on the self-renewal, proliferation, and differentiation of HSCs (Chen et al., 2008; 
Pittenger et al., 1999) and are able to differentiate into various other stromal cells 
normally present in the BM, such as adipocytes and osteoblasts. Nevertheless, the 
engraftment of transplanted human MSCs at murine sites of haematopoiesis is not very 
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efficient, maybe due to competition with a functional murine microenvironment. It was 
only until the development of human 3-dimensional bone-tissue-like structures using 
scaffolds that revolutionized these efforts (Nichols et al., 2009; Song et al., 2010). Since 
Polyurethane, 3D poly-e-caprolac-tone polymeric and high-performance titanium-based 
scaffolds coated with human MSCs result in human bone formation (Calimeri et al., 2011; 
Lai et al., 2013) were shown to effectively allow engraftment of human cancer cells thus 
allowing creation of ectopic human niches (Calimeri et al., 2011; Vaiselbuh et al., 2010).  
Along the same line, the Martens lab has recently also developed a novel humanized 
mouse model that allows the study of the in vivo interactions between BM stromal cells 
and human haematopoietic and leukemic cells (Groen et al., 2012). This model 
implements a scaffold-based technology in which culture-expanded BM-derived stromal 
cells are loaded on biphasic calciumphosphate (BCP) particles which are then implanted 
subcutaneously on the dorsal side of RAG2-/-γc-/- mice (Figure 5A). Eight weeks after 
implantation, human OBs grow out on top of a layer of human bone in connection with 
vessels capable of supporting haematopoiesis thus generating a human BM 
environment (Figure 5B). Inoculation of these mice with umbilical cord blood-derived 
CD34+ results in their engraftment and differentiation into multiple blood cell lineages 
(Figure 5C). This humanized model has been tested for the engraftment and growth of 
a multiple myeloma (MM) cell line and for patient-derived MM (pMM) cells, and showed 
successful support of both types of cells. We have shown that these BM ectopic niches 
support the growth of primary human B-ALL cells (data not shown). Therefore, this novel 
mouse model allows the study of the human haematopoietic niche in the context of 
normal and malignant haematopoiesis. Since this model is based on in vitro cultured 
human MSCs, this provides the opportunity for genetic manipulation of the BM 
microenvironment, either by overexpressing, silencing or deletion of specific genes. 
52 
 
Figure 5 - The in vivo generated humanized bone 
microenvironment. (A) Schematic representation of 
the scaffold model. (B) RAG2-/-γc-/- mice were 
implanted with human MSC-loaded BCP scaffolds (s). Eight weeks after implantation, this led to the 
formation of human bone (b) in the vascularized (v) open spaces that was capable of supporting mouse 
hematopoiesis. (C) CD34+ cells engraft and differentiate in humanized ossicles. At week 16 ossicles with 
human CD45+ cells (CD45) were revealed. These included B cells (CD20), T cells (CD3), and myeloid cells 
(CD15). Undifferentiated CD34+ cells (CD34) were detected adjacent to both bone (b) and vessels (v). 
(Adapted from Groen et al., 2012) 
 
Recently, Chen et al. have developed an in vivo extramedullary bone model in 
NOD/SCID/IL-2rγnull mice by subcutaneously injecting them with a matrigel scaffold 
seeded with human BM-derived MSCs mixed with endothelial colony-forming cells 
(EPCs) (Chen et al., 2012). This is the first model in which both the stroma and the 
endothelium are humanized, besides showing the usefulness of the humanized BM niche 
as a tool to study the role of certain factors by genetically manipulating these niches. 
In summary, the humanized mouse models mentioned here are state of the art 
technology to study the interactions of tumour cells with the BM microenvironment, 
including studying the influence of BMSCs-derived factors on the growth of human B-
ALL in vivo. Thereby these open up a new field of research into the in vivo role of the BM 
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niche in human B-ALL growth, in addition to other leukaemias and normal 
haematopoiesis. 
 
1.4.1.1.1. The CRISPR/Cas System 
One way to establish the importance of one particular stroma-derived factor in the BM 
microenvironment is to reduce or ablate its expression. In addition to the commonly used 
shRNA approach that allows down regulation of genes of interest, so called knock down, 
recent advances have been made in genome editing that even allow the generation of 
human knock out cells. Recently, an efficient technique that allows genome editing has 
been developed based on a system that bacteria and archae use in their immune 
defence (Wiedenheft et al., 2012), termed Clustered Regularly Interspaced Short 
Palindromic Repeats or CRISPR/Cas system (Cong et al., 2013; Mali et al., 2013). This 
system relies on a single-guide RNA (gRNA) that directs Cas9, an endonuclease, to its 
complementary DNA sequence in the genome. After binding, Cas9 cleaves the DNA in 
both strands therefore creating a double strand break (DSB). The cell activates 
mechanisms to repair these DSBs. If they are repaired by error-prone non-homologous 
end-joining (NHEJ), this can result in the introduction of deletions or insertions, which 
may generate frameshift mutations. Therefore, this cellular repair mechanism can lead 
to a knock out of the gene targeted with the gRNA. Alternatively, another DNA repair 
mechanism can be activated: the homology-directed repair (HDR), in which case it is 
possible to either add or correct a gene since it requires a homologous DNA segment for 
the process (Figure 6) (Charpentier and Doudna, 2013; Gaj et al., 2013; Sander and 
Joung, 2014). 
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Figure 6 - Targeted genome editing in human cells using CRISPR/Cas system. (adapted from Mali et.al, 
2013) 
 
Due to its enormous potential, the CRISPR/Cas system is being widely used and exciting 
breakthroughs have been made. For instance, a dominant mutation that causes a 
genetic disease has been corrected in mice by HDR (Wu et al., 2013). Even more 
impressive, monkeys genetically-modified in a precise target gene have been recently 
generated (Niu et al., 2014). This genome engineering technique can have different 
applications as well, such as in human genetic screening (Wang et al., 2014).  
In summary, the CRISPR/Cas system is certainly going to transform biological research 
and impulse the development of novel and more successful therapies. Particularly, this 
technique in combination with the scaffold model can be used to study the role of stromal 
factors in haematopoiesis/leukemia. As it allows the genomic edition of human MSCs, 
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we can either totally ablate a target gene, thus determining its importance for B-ALL, or 
label it, which should allow the tracking of (cells expressing) these factors. 
 
1.5. Scope and aims of this thesis 
The main goal of the present study was to setup techniques to study the role of various 
stromal-derived factors in supporting human B-ALL growth in vivo. For this purpose, we 
aimed at generating ectopic humanized niches in immunocompromised mice that upon 
induction lose the expression of the studied factors. In addition, we wanted to study the 
effect of total ablation of the selected stromal factors. The importance of these factors in 
leukaemia can be addressed by analysis of the engraftment and growth of primary 
human B-ALL samples in such BM niches. 
The specific aims of this project were: 
a. To confirm the in vitro capacity of BM MSCs to support the growth of B-ALL cells; 
b. To determine the biological function of the studied stromal factors in B-ALL in 
vitro and to develop assays that allow functional validation of the genetic 
manipulated MSCs; 
c. To generate and validate inducible knock down MSCs for CXCL12, VCAM-1 and 
IL-7 and to investigate their biological effect on B-ALL cells in vitro; 
d. To generate knock out MSCs for CXCL12 and VCAM-1 using the CRISPR/Cas 
system followed by validation at the protein and functional level; 
e. To test if the genetically manipulated MSCs are able to form ectopic human bone 
marrow niches in vivo. 
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2. Materials and Methods 
2.1. Materials 
The plasmids pH1tet-flex and pFH1t(INSR)UTP were obtained from Taconic Artemis and 
pRP-418 was kindly provided by Robert Jan Lebbink (Emmanuel Wiertz lab, UMC 
Utrecht). The oligonucleotides were purchased from Sigma Aldrich. 
The human B cell precursor leukaemia cell lines, REH, NALM-6, MHH-CALL4 (CALL4), 
NALM-6 lentiviral transduced with Luc-mCherry-Puromycin (Puro), and REH with Luc-
mCherry-Puro, were provided by the group of Monique den Boer (EMC Rotterdam). 
NALM-6 cells were lentiviral transduced with Luciferase (Luc)-Green Fluorescent Protein 
(GFP) by Anne van der Leun. 
The human recombinant IL-7, TSLP and CXCL12 were obtained from Immunoblots. The 
FC Receptor Block (anti-CD16/32), CXCR4-PE (anti-CD184) and IL-7-Rα-PE (anti-
CD127) antibodies were purchased from BD Bioscience and the TSLPR-PerCP and 
VCAM-1-PerCP (anti-CD106) antibodies from eBioscience. Tra-1-85-FITC (R&D 
systems) was used. Poly(ethylenimine) was purchased from Polysciences. 
AMD3100 (Sigma) was kindly provided by Debby Gawlitta (Wouter J.A. Dhert lab, UMC 
Utrecht). TNFα was acquired from Immunotools. Doxycycline hyclate (DOX) and 
Puromycin were obtained from Sigma Aldrich.  
 
2.2. Animals 
The animal experiments were performed according to the Dutch guidelines on animal 
experimentation and ethically approved by the local Animal Experimentation Committee. 
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2.3. Cell culture 
After written informed consent and approval by the Institutional Medical Ethical 
Committee to use the material for research purposes only, extracts from the BM of 
healthy donors were obtained. MSCs were obtained from the BM of the healthy donors, 
hereafter mentioned as Donor 99 (D99) or Donor 06 (D06) cells, and cultured at 37ºC 
5% CO2 in MSC medium consisting of MEM alpha medium (Gibco) supplemented with 
10U/ml Heparin (Leo Pharma), 1% Penicillin/Streptomycin (Invitrogen) and 5% platelet 
lysate (PL), which was provided by the Bloodbank Sanquin Northwest (Utrecht, The 
Netherlands) and consisted of a pool of PL from 5 different donors (MSC medium with 
PL). NALM-6-Luc-GFP, NALM-6-Luc-mCherry-Puro and REH-Luc-mCherry-Puro cells 
were cultured at 37ºC 5% CO2 in RPMI-1640, GlutaMax (Gibco) supplemented with 10% 
heat inactivated HyClone Fetal Bovine Serum (FBS) (GEHealthcare) and 1% 
Penicillin/Streptomycin (Invitrogen). CALL4 cells were cultured at 37ºC 5% CO2 in RPMI-
1640, GlutaMax (Gibco) supplemented with 20% FBS (GEHealthcare) and 1% 
Penicillin/Streptomycin (Invitrogen). Inducible (ind) knock down (KD) BM MSCs were 
cultured in Tet-free medium (DOX free medium) consisting of MEM alpha medium 
(Gibco) supplemented with 1% Penicillin/Streptomycin (Invitrogen), 10% FBS provided 
by the Patrick Derksen group (UMC Utrecht) that had been tested to not induce 
downregulation of genes in cells that were transduced with inducible shRNAs, L-
glutamine (2 mM, Gibco), fibroblast growth factor (b-FGF, 1 ng/ml, Invitrogen) and L-
ascorbic acid 2-phosphate (0.2 mM, Sigma Aldrich). To test if there was leakiness in the 
inducible system and to determine which was the optimal medium for culturing the indKD 
MSCs, these MSCs were cultured as well in an MSC medium similar to DOX free 
medium, only differing on the supplemented FBS, which was HyClone Fetal Bovine 
Serum (MSC medium with FBS, GEHealthcare). 
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2.4. Co-culture of B-ALL cells and BM MSCs and Luciferase Activity 
Measurement 
In order to assess expansion of B-ALL cells NALM-6-Luc-mCherry-Puro and REH-Luc-
mCherry-Puro cells were co-cultured in the presence of MSCs in a 1:1 mixture of RPMI-
1640, GlutaMax (Gibco) supplemented with 5 µg/ml insulin, transferrin and sodium 
selenite (ITS, Invitrogen) and 1% Penicillin/Streptomycin (Invitrogen), and MEM alpha 
medium (Gibco) supplemented with 1% Penicillin/Streptomycin (Invitrogen) and 5µg/ml 
ITS (Invitrogen). In order to reach the best ratio MSCs:B-ALL cells, different numbers of 
MSCs (825, 1650, 3300 and 6600) were seeded in a white polystyrene 96 wells assay 
plate (Costar). After 3-4h, B-ALL cells were added in three different concentrations 
(9,38x10^3 cells/ml, 1,88x10^4 cells/ml and 3,75x10^4 cells/ml) in a total volume of 100 
µl per well. The cells were incubated at 37ºC 5% CO2 for 3 days. To determine the 
relative degree of B-ALL cells expansion, we measured the luciferase activity in each 
respective well by adding 4 µl of Luciferine (Promega) and by measuring the 
bioluminescence at 550 nm (Ugarova, 1989) using a Centro LB 960 Microplate 
Luminometer (Berthold Technologies). The optimized numbers of MSCs and B-ALL cells 
used in the follow up experiments were 1650, 3300 or 6600 cells and 3,75x10^4 cells/ml, 
respectively. Expansion of NALM-6-Luc-mCherry-Puro cells (3,75x10^4 cells/ml) when 
co-cultured with VCAM-1 constitutive KD MSCs (6600 MSCs) in the presence or 
absence of 20 ng/ml Tumor Necrosis Factor alpha (TNFα, Immunotools) was analysed. 
To test the effect of IL-7 on the expansion of co-cultured B-ALL cells, NALM-6-Luc-
mCherry-Puro cells (3,75x10^4 cells/ml) were cultured in the presence of 1650 or 3300 
BM MSCs, IL-7 (100ng/ml) (Immunoblots) and 0.25 ng/ml DOX (Sigma Aldrich). After 
three days, Luciferase Activity was measured. 
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2.5. Migration Assays 
To test whether B-ALL cells migrate in response to CXCL12, NALM-6-Luc-GFP cells 
(5x10^6 cells/ml) were incubated for 30min at 4ºC in the presence or absence of 
AMD3100 (10µg/ml, Sigma). MSC medium containing CXCL12 (100ng/ml, Immunotools) 
+/- AMD3100 (10µg/ml) was added to the bottom chamber of Corning Transwell 
polycarbonate membrane cell culture inserts (Sigma Aldrich). NALM-6-Luc-GFP cells 
(5x10^5 cells) were added to the top chamber. After 3h incubation at 37ºC 5%CO2, the 
presence of B-ALL cells in the bottom chamber was determined by measuring the 
Luciferase Activity as described above. 
 
2.6. Presto Blue Cell Viability Assay 
To determine CALL4 growth, cells (6x10^5 cells/ml in 100 µl, 96 well plate round bottom) 
were incubated with 10ng/ml or 100ng/ml of human recombinant TSLP (Immunoblots) in 
RPMI 10%FBS medium for 3 days at 37ºC 5%CO2. PrestoBlue® Cell Viability Reagent 
(Invitrogen) was added (10µL/well) and cells were incubated at 37ºC 5%CO2 for 30-45 
minutes. Fluorescence was read at 560nm (excitation)/590nm (emission) using a 
Spectramax Plus384. 
 
2.7. Quantitative Real Time-Polymerase Chain Reaction for mRNA (qRT-
PCR) 
To validate the inducible knock down of the selected factors in ind KD MSCs, these cells 
were incubated for either 16h (400,000 cells), 24h (200,000 cells), 48h (180,000 cells) 
or 5 days (18,000 cells) in the presence of DOX (Sigma Aldrich) (0.25µg/ml), added every 
two days. The RNA was isolated using RNeasy Mini Kit (Qiagen) following the 
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manufacturer’s instructions. cDNA was synthesized using 5x iScript Reaction mix 
(Biorad) and iScript Reverse Transcriptase (Biorad) according to the manufacturer’s 
instruction and incubating at the following temperatures: 25ºC 5min, 42ºC 45min, 85ºC 
5 min, 4ºC. cDNA was diluted 1:10 with RNase-free water. For the qRT-PCR reaction, 
the samples were added to a mix of forward and reverse primers (10 µM, see table) and 
Sybr® Green Super mix in a total volume of 15µl per sample. The reactions were 
performed at the following temperatures: 95ºC 3min (1 cycle); 95ºC 30s, 60ºC 30s, 72ºC 
30s, 95ºC 1min (40 cycles); 65ºC 1min, 65ºC 10s (30 cycles), 4ºC. The quantification 
analysis was based on the detection of a fluorescence signal obtained when SYBR® 
Green intercalates in the DNA double strand, which is proportional to the amount of 
amplified DNA. All reactions were performed in triplicate. The expression of Beta-2-
microglobulin (B2M) was used to normalize the expression of the target DNA. 
 
Table 1 - qRT-PCR primers 
Gene Forward primer (5’-3’) Reverse primer (5’-3’) 
hCXCL12 ATTCTCAACACTCCAAACTGTGC ACTTTAGCTTCGGGTCAATGC 
hIL-7  TCTAATGGTCAGCATCGATCA GTGGAGATCAAAATCACCAGT 
hVCAM-1 GGACCACATCTACGCTGACA TTGACTGTGATCGGCTTCCC 
hB2M ATGAGTATGCCTGCCGTGTGA GGCATCTTCAAACCTCCATG 
 
2.8. Enzyme-linked Immunoabsorbent assay (ELISA) 
Quantitative analysis of the presence of CXCL12 in the medium of CXCL12 indKD 
MSCs, CXCL12 KO MSCs and their respective Scrambled (Scr) MSCs was performed 
using Quantikine ELISA (R&D Systems) according to the manufacturer’s 
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recommendations. This assay was performed with conditioned medium that was 
collected after 3 days of cell culture (35000 cells per well in a 24WP) and stored at - 
80ºC. IndKD MSCs had been previously cultured for 7 days in medium with PL in the 
presence of 0.25 ng/ml DOX, added every two days. Briefly, 100µl conditioned medium 
was added to the 96 well plate (R&D Systems) already containing Assay Diluent and 
incubated for 2h at room temperature (RT) on a horizontal orbital microplate shaker set 
at 500±50 rpm. After washing the wells, CXCL12 conjugate was added to each well and 
the plate was incubated at RT as mentioned above. The substrate solution was added 
and the plate was incubated for 30 min on the bench top. The optical density was 
determined using Spectramax Plus384 set to 450nm. Optical corrections were made by 
measuring the optical density at 540nm as well. 
 
2.9. Adhesion Assays 
With the aim of determining if knocking out VCAM-1 in BM-MSCs affected the adhesion 
of B-ALL cells to the stromal cells, NALM-6-Luc-mCherry-Puro cells (3,75x10^4 cells/ml) 
were cultured in the presence of VCAM-1 KO MSCs (3300 or 6600 MSCs per well) and 
±  20 ng/ml TNFα (Immunotools), as described previously. After 24h incubation at 37ºC 
5% CO2, the plate was placed for 5 min in a horizontal orbital microplate shaker set at 
450±50 rpm. The medium was collected (aproximatelly 100 µl per well) and transferred 
to a new well. Phosphate-buffered saline (PBS) was added (150 µl per well) to the 
remaining cells in the bottom and the plate was placed for 5 min in a horizontal orbital 
microplate shaker set at 450±50 rpm. The PBS was removed and the previous step was 
repeated. After aspiration of the PBS, new medium was added (100 µl). Luciferase 
Activity was determined. 
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2.10. Vectors Construction 
Aiming at obtaining BM MSCs with inducible knock down of certain stromal derived 
factors, we used the DOX-inducible system from TaconicArtemis in which we cloned 
shRNAs into the pH1tet-flex/FH1t(INSR)UTP vector system. 
After vector amplification through Escherichia coli (DH5α cells) transformation by heat 
shock and plasmid DNA isolation (Genopure Buffer Set, Roche) following the 
manufacturer’s instructions, 1 µl Bovine Serum Albumine (BSA, New England BioLabs), 
5 µl buffer 2 (New England BioLabs) and 30 µl deionized water, and the 
pFH1t(INSR)UTP vector (1.3 µg/µl, 12 µl) with 1 µl PacI (New England BioLabs), 1 µl 
Bovine Serum Albumine (BSA, New England BioLabs), 5 µl buffer 1 (New England 
BioLabs) and 31 µl deionized water, were digested both at 37ºC during 2,5h. The 
pFH1t(INSR)UTP vector (44 µl) was dephosphorylated with 1 µl Phosphatase Alcaline 
(Roche) and 5 µl 10x dephosphorylation buffer (Roche) during 1h at 37ºC, and then 
purified using High Pure PCR Product Purification Kit (Roche) according to 
manufacturer’s instructions. Oligonucleotides containing the shRNA sequence (see 
Table 2) were annealed – 10 µl top strand, 10 µl bottom strand and 80 µl Annealing 
Buffer (10 mM Tris pH 7.5, 1 mM EDTA and 50 mM NaCl). Then, the annealed 
oligonucleotides were diluted (1:100) and cloned into the digested pH1tet-flex vector. For 
the ligation reaction, 2 µl pH1tet-flex vector (20.3 ng/ml), 2 µl annealed oligonucleotides, 
13 µl deionized water, 2 µl T4 DNA ligase buffer (Roche) and 1 µl T4 DNA ligase were 
incubated O/N at 16ºC. Following bacteria transformation with the ligated vectors, 
colonies were picked and plasmid DNA was isolated. Positive colonies were sequenced. 
Plasmids containing the correct DNA sequence were amplified though PCR and digested 
with PacI. Then the inserts (4,64 ng) were cloned in a 1:3 ratio into PacI-digested 
pFH1t(INSR)UTP (3,3 µl, 50 ng), 12 µl deionized water, 2 µl T4 DNA ligase buffer 
(Roche), 1 µl T4 DNA ligase  and 1 µl ATP (10 mM), O/N at 16ºC. The end product was 
also sequenced. 
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Table 2 - DNA sequence of shRNAs 
 
Target Sense Anti-sense 
CXCL12 tcccCGTCAGCCTGAGCTACAGATTCAAG
AGATCTGTAGCTCAGGCTGACGtttttc 
TCGAgaaaaaCGTCAGCCTGAGCTACAGAT
CTCTTGAATCTGTAGCTCAGGCTGACG 
IL-7 tcccAAGGTATCAGTTGCAATAATTCAAG
AGATTATTGCAACTGATACCTTtttttc 
TCGAgaaaaaAAGGTATCAGTTGCAATAATC
TCTTGAATTATTGCAACTGATACCTT 
TSLP tcccCTATTCGGAAACTCAGATATTCAAG
AGATATCTGAGTTTCCGAATAGtttttc 
TCGAgaaaaaCTATTCGGAAACTCAGATATC
TCTTGAATATCTGAGTTTCCGAATAG 
VCAM-1 tcccTGGAGATAGACTTACTGAATTCAAG
AGATTCAGTAAGTCTATCTCCAtttttc 
TCGAgaaaaaTGGAGATAGACTTACTGAAT
CTCTTGAATTCAGTAAGTCTATCTCCA 
 
To generate BM MSCs knocked out for the factors of interest, the CRISPR/Cas9 system 
was used. The backbone vector pRP-418 was digested with EspEI (Thermo scientific) 
at 37ºC O/N by Ester Rieter (UMC Utrecht). Oligonucleotides containing the target 
sequence (see Table 3) were annealed as described above. Then, annealed 
oligonucleotides (0.52ng, 1:1000 dilution) were cloned in a 1:5 ration into the digested 
pRP-418 vector (28,7 ng/µl, 2 µl), 12 µl deionized water, 2 µl T4 DNA ligase buffer 
(Roche), 1 µl T4 DNA ligase  and 1 µl ATP (10 mM), O/N at 16ºC. Following bacteria 
transformation with the ligated vectors, colonies were picked and plasmid DNA was 
isolated. Positive colonies were sequenced.  
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Table 3 - DNA sequence of CRISPR oligonucleotides 
 
Target Oligonucleotide 
CXCL12_1 accgACCTTGGCGTTCATGGCGC 
CXCL12_2 accgAGATGCTTGACGTTGGCTC 
VCAM-1_1 accgGGAAGATGGTCGTGATCCT 
VCAM-1_2 accgACCAAGACGGTTGTATCTC 
VCAM-1_3 accgAGGCTGTAGCTCCCCGTTA 
CD44_1* TGGAAAGGACGAAACACCGCGCCAGGCTCAGCGGCACGGTTTTAGAGCTAGAA 
CD44_2* TGGAAAGGACGAAACACCGGCACTCACCGATCTGCGCCGTTTTAGAGCTAGAA 
CD44_3* TGGAAAGGACGAAACACCGGGACTGTCTTCGTCTGGGAGTTTTAGAGCTAGAA 
* CD44 CRISPR lentivirus media were kindly provided by Robert Jan Lebbink (Emmanuel Wiertz lab, UMCU) 
and a different method for generating the KO vectors was used (Robert Jan Lebbink, unpublished). 
 
2.11. Production of Lentivirus 
HEK293T cells (1,5x10^6 cells per 9cm culture dish) were seeded in DMEM (Invitrogen) 
with 10% FBS, 1% Penicillin/Streptomycin (Invitrogen). Next day, the medium was 
replaced and cells were transfected with a mixture of 2µg shRNA previously generated, 
1,2 µg pHDM-HgpM2, 1,2 µg pRC-CMV-Rev1b, 1,2 µg pHDM-tat1b and 2,4 µg pHDMG-
G with Poly(ethylenimine) (6µg/ml, PEI, Polysciences), which had been incubated for 
15min at RT. After 24h the medium was refreshed. At 2 and 3 days post transfection the 
medium was collected, filtered and then stored at -80ºC (lentivirus medium). 
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2.12. Transduction of MSCs with Lentivirus 
Low passage D06 BM MSCs were plated in a 6 well plate (25000 cells or 50000 cells 
per well). After 24h, the medium was replaced with 2 ml MSC medium, 1 ml of lentivirus 
medium and Polybrene (6µg/ml, Sigma Aldrich). The next day the medium was 
refreshed. Three days after transduction the medium was refreshed again and 
Puromycin (Sigma) was added (2µg/ml). Six days post transduction, the medium was 
refreshed. 
 
2.13. Transfection of MSCs using Neon Electroporation 
Transfection of D06 with a small vector (4,700bp) encoding GFP (sGFP), a big (9,289bp) 
GFP vector (bGFP), VCAM-1 tg1 and tg3 and CD44 tg2 CRISPR vectors was performed 
using the Neon® Transfection System (Life Technologies) according to the 
manufacturer’s instructions. Briefly, 0.5x10^6 cells were resuspended in 100µl Neon® 
Buffer R (Life Technologies) and 1µg of the plasmid was added. The samples were 
aspirated into the Neon® Pipette. Cells were electroporated in Neon® 100µl tips using 
the following settings: (A) 1600 V, 20 ms, 1 pulses; (B) 1000 V, 40 ms, 1 pulse or (C) 
1400 V, 10 ms, 2 pulses. Immediately after electroporation, cells were plated in MEM 
alpha medium supplemented with 10% FBS without antibiotics. After 24h, the medium 
was replaced with MEM alpha medium supplemented with 10% FBS and 1% 
Penicillin/Streptomycin (Invitrogen). Two days after transfection, Puromycin (1mg/ml) 
was added to select the cells that had been transfected with CRISPR vectors. After two 
days the medium was replaced with regular MSC medium (with PL). 
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2.14. Generation of humanized bone in Mice 
The in vivo generation of human bone from MSCs seeded on BCP scaffolds was 
performed as described previously (Groen et al., 2012). Briefly, to test the ability of 
constitutive KD MSCs to form bone, 3 BCP scaffolds per mouse were loaded with 
CXCL12, IL-7 or TSLP constitutive KD BM MSCs (generated by Anne van der Leun) and 
implanted subcutaneously into 3 RAG2-/-γc-/- mice. As control, one scaffold was loaded 
with wild-type (wt) human MSCs and another with MSCs KO with scrambled gene target, 
per mouse. Eight weeks after implantation, the mice were euthanized and scaffolds were 
isolated from the skin of the mice and fixed in 4% formaldehyde for 24h. After one week 
incubation in 12.5% EDTA 1,25% NaOH pH7 to decalcify and overnight (O/N) incubation 
in 70% EtOH, the scaffolds were embedded in paraffin and placed into blocks. To test if 
the indKD MSCs were able to form bone, scaffolds seeded with Scr1, VCAM-1 or 
CXCL12 indKD MSCs were implanted in 6 mice. Six weeks after implantation, three of 
the mice were injected intraperitoneally twice per week with DOX (125 µg/mouse)  and 
DOX (1mg/ml) was also added to their water, containing 5% sucrose (Reijmers et al., 
2010). Two weeks after, the mice were sacrificed. Half of the scaffolds were isolated and 
embedded in paraffin as described above. The other half were treated with Collagenase 
D (Roche), stained with Tra-1-85-FITC and FACS sorted according to the expression of 
human TRA‑1‑85 antigen, a pan-human antigen. Total RNA was extracted from these 
cells. In addition, VCAM-1 expression in VCAM-1 indKD cells was determined by flow 
cytometry. All the in vivo experiments were performed together with Anita Govers, Paul 
Coffer’s group, UMC Utrecht. 
 
2.15. Hematoxilin and Eosin Staining of Mice Scaffolds 
Sections were cut and stained with Hematoxilin and Eosin (H&E) (Klinipath). Briefly, 
following xylene and decreasingly graded alcohol solutions, sections were 
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counterstained with hematoxylin, washed, incubated in eosin. They were subsequently 
dehydrated through graded alcohol, cleared in xylene, and covered with a coverslip. 
 
2.16. Flow Cytometry and Cell Sorting 
In order to analyse receptor downregulation, CALL4 cells were incubated O/N at 37ºC 
5% CO2 with the respective ligand and then analysed using antibodies against human 
CXCR4 (CXCR4-PE, BD Bioscience), IL-7Rα (IL-7R-PE, BD Bioscience) or TSLPR 
(TSLPR-PerCP, eBioscience). Sytox Blue Dead Cell Stain (Invitrogen) was used to 
exclude dead cells. Analysis of the expression of VCAM-1 in both indKD and KO MSCs 
(40,000 cells)  cultured during 3 to 7 days was performed after 12-16h incubation at 37ºC 
5% CO2 with TNFα (10ng/ml) using antibody directed against VCAM-1 (VCAM-1-Pe, 
eBioscience). To determine if contact with B-ALL cells leads to VCAM-1 upregulation on 
MSCs, Scr1 and VCAM-1 ind KD MSCs (320,000 cells) that had been cultured for 3 days 
in the presence of DOX (0.25 ng/ml), were co-cultured (3300 MSCs) with NALM-6-Luc-
mCherry-Puro (3,75x10^4 cells/ml) and then analysed using VCAM-1-Pe (eBioscience). 
In addition, MSCs were cultured in conditioned medium from B-ALL cells that was 
harvested from NALM-6-Luc-mCherry-Puro (0.6x10^6 cells/ml) that had been cultured 
for one day in RPMI medium supplemented with 1% Penicillin/Streptomycin (Invitrogen) 
and 5µg/ml ITS (Invitrogen). All acquisitions were performed on a FACSCanto II or a 
FACS LSRII flow cytometers with FACSDiva Version 6.1.3 software (BD Biosciences). 
The data obtained was analysed by FlowJo. 
With the aim of obtaining single clones from BM MSCs, wt MSCs (D06 and D99) or Scr1 
and VCAM-1 KO MSCs that had been incubated during 12-16h at 37ºC 5% CO2 with 
TNFα (10ng/ml), when indicated, were sorted into 96 well plates (1 cell per well, 48 or 
95 wells per cell type) using a FACS Aria II cytometer with FACSDiva Version 6.1.3 
software (BD Biosciences). The sorting of VCAM-1 KO MSCs was based on their VCAM-
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1 expression which was analysed using antibody directed against VCAM-1(VCAM-1-Pe, 
eBioscience). 
 
2.17. Statistical Analysis 
Data is presented as mean ± standard deviation (SD) when two or three independent 
experiments were performed. As indicated, in some cases experiments were only 
performed once, in which case the data is presented as mean ± SD of duplicates or 
triplicates. Non-parametric Mann-Whitney two-tailed test was used when three 
independent experiments were performed. GraphPad Prism 5 was used for these 
tests/calculations. 
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Chapter 3     Results 
 
 
 
 
 
 
 
 
 
 
 
72 
 
3. Results 
3.1. The role of specific stromal-derived factors in the growth and 
survival of B-ALL cells in vitro and in vivo 
As discussed, the crucial role of BM stromal cells in the growth and survival of B-ALL 
cells has been demonstrated (Bradstock et al., 1996; Gluck et al., 1989; Umiel et al., 
1986), particularly when these cells are maintained in direct contact (Manabe et al., 
1994). This supports the idea that there may be certain molecules such as cytokines, 
chemokines and adhesion factors, which are responsible for this enhanced survival and 
proliferation of cancer cells. Therefore, a better understanding of which stroma-derived 
factors are responsible for this effect and hence a better knowledge of the biology of 
leukemic BM can lead to a considerable improvement in therapeutics. 
 
3.1.1.  BM MSCs support expansion of B-ALL cell line NALM-6 
First, we wanted to determine if the BM stromal cells that we had obtained from a healthy 
donor (D06) were able to support the proliferation of B-ALL cell lines. In order to do so, 
the luciferase-containing B-ALL cell lines NALM-6-Luc-mCherry-Puro and REH-Luc-
mCherry-Puro were cultured in the presence of different numbers of MSCs. The 
expansion of the B-ALL cells was monitored by adding luciferine upon which luciferase 
converts it in a reaction that emits light. By quantifying the luminescent signal obtained 
after three days and comparing it to the signal of the first day, we calculated the relative 
growth (fold induction) and observed that NALM-6 cells expanded when in co-culture 
with BM MSCs (Figure 7a). Under the conditions used, this B-ALL cell line was unable 
to survive in the absence of MSCs. With the lowest amount of MSCs, MSCs induced 
survival of NALM-6 rather than expansion. The expansion effect due to the contact with 
MSCs was enhanced with increasing numbers of MSCs, reaching up to four (1650 
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MSCs) or six (3300) times the initial number of NALM-6 cells. On the other hand, the 
amount of NALM-6 cells had only slight effects on their survival/expansion, especially in 
the presence of no or low amounts of MSCs. In contrast to NALM-6 cells, REH cells were 
not able to proliferate even in the presence of MSCs (Figure 7B). However, MSCs 
improved the survival of these B-ALL cells, especially when higher amounts of MSCs 
were used in the co-cultures. Furthermore, for both cells lines, the support of BM MSCs 
was lost not only when higher amounts of either MSCs or leukemic cells were cultured 
but also if other MSCs:B-ALL cells ratios were used (data not shown). Together these 
results, confirm the ability of BM MSCs to induce the survival and, in case of NALM-6 
cell line, also the expansion of B-ALL cells. 
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(previous page) Figure 7 - BM MSCs support expansion of B-ALL cell line NALM-6 in vitro. NALM-6-
Luc-mCherry-Puro cells (NALM-6) (A) and REH-Luc-mCherry-Puro (REH) (B) were cultured for 3 days at 
the indicated concentrations on top of different numbers of D06 BM MSCs. Fold induction (FI) of the 
luminescence as compared to the luminescence obtained on day 0 for each concentration of B-ALL cells. 
Results represent two independent experiments. 
 
3.1.2. Responsiveness of B-ALL cell lines to CXCL12 and IL-7, but 
not to TSLP 
Many BM-derived stromal factors have been described to play a role in B-ALL growth 
(Tabe and Konopleva, 2014). However, these conclusions were mainly drawn based on 
in vitro studies, which have many limitations, or in vivo experiments where the human 
BM microenvironment was not properly simulated. The overall aim of our study is to 
determine if certain stromal factors are indeed important for B-ALL growth using a novel 
in vivo model that allows the generation of an ectopic human niche in immunodeficient 
mice. We have focused on studying the role of CXCL12, IL-7 and VCAM-1, factors that 
have been demonstrated to be critical in the interaction between BM MSCs and B-ALL 
cells (Bradstock et al., 2000; Filshie et al., 1998; Hall et al., 2004a; Juarez et al., 2007a; 
Rich et al., 1993; Sipkins et al., 2005b). In addition, due to the similar biological function 
as IL-7 and lack of appropriate studies on the role of TSLP in B-ALL growth, we decided 
to also take this cytokine along (Brown et al., 2007). Our first goal was to confirm previous 
literature that in vitro B-ALL cell lines are responsive to the selected factors and that 
these factors affect the growth (IL-7 and TSLP) or chemotaxis (CXCL12) of B-ALL cells. 
In addition, these assays were also developed to functionally validate the genetically 
manipulated MSCs (see below). 
As a first test of responsiveness, we used flow cytometry to analyse the levels of 
expression of the receptors for the ligands of interest in the B-ALL cell lines CALL4 and 
NALM-6-Luc-mCherry-Puro upon overnight exposure to the respective ligands. Since 
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receptors are internalized upon interaction with their respective ligand (Henriques et al., 
2010; Neel et al., 2005), this allows us to determine the responsiveness of B-ALL cells 
for IL-7, CXCL12 and TSLP by quantifying the expression levels of their receptors, IL-
7Rα, CXCR4 and TSLPRα (TSLPR), respectively. The expression of IL-7Rα and CXCR4 
in CALL4 cells decreased after overnight treatment with IL-7 and CXCL12, respectively, 
confirming their sensitivity to these stromal factors (Figure 8). The heterodimeric TSLP 
receptor is comprised of TSLPRα (here mentioned as TSLPR) and IL-7Rα (He and 
Geha, 2010). Overnight incubation with TSLP induced downregulation of IL-7Rα in 
CALL4, but not of TSLPR. Similar results were obtained with overnight stimulation of the 
NALM-6 cell line (data not shown). 
To determine whether the induction of receptor downregulation also led to a biological 
significant response, we analysed B-ALL growth when cells were treated with IL-7 or 
TSLP and migration of B-ALL cells towards CXCL12. CXCL12-induced leukemic cell 
expansion was analysed, but CXCL12 didn’t stimulate expansion of B-ALL cells (data 
not shown). The chemotaxis effect of CXCL12 was determined using a transwell assay 
in which migration of NALM-6-Luc-mCherry-Puro cells was analysed using luciferine-
induced luminescence. The results are represented as percentage of luminescence 
relative to luminescence of the initial number of B-ALL cells added. CXCL12 in the lower 
chamber induced an increase of approximately 14% in the migration of B-ALL cells, in 
comparison to the cells that already migrated towards MSC medium (2,3%, Figure 9A). 
This effect was abrogated when AMD3100, an inhibitor of CXCR4 signalling, was added 
in combination with CXCL12, indicating that the chemotaxis observed is dependent on 
CXCL12. Quantification of migrated cells by flow cytometry confirmed these results (data 
not shown). 
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Figure 8 – B-ALL cell line CALL4 respond to CXCL12, IL-7 and TSLP stimulation. B-ALL cell line MHH-
CALL4 (CALL4, 6x10^5 cells/ml) was treated overnight with 100 ng/ml IL-7, CXCL12 or TSLP and the 
expression of the respective receptors (IL-7Ralpha, CXCR4 and TSLPR) was analysed by flow cytometry. 
Untreated cells are shown in grey and ligand-treated cells in blue. Graphs represent the mean fluorescence 
intensity (MFI) of duplicates of the same experiment. Results are representative of two independent 
experiments.  
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For testing the effect of IL-7 and TSLP on B-ALL growth, we used NALM-6-Luc-mCherry-
Puro and CALL4 cells. In line with the results in Figure 7A, at the cell concentrations 
used NALM-6 cells that were cultured in the absence MSCs or without addition of a 
growth factor were not able to survive (Figure 9B). However, addition of IL-7 (100ng/ml) 
led to their survival and caused some slight expansion (2.3 ± 1.8 fold). This effect of IL-
7 was even enhanced when the B-ALL cells were co-cultured with BM MSCs (11.5 fold, 
3300 MSCs). Similar results were obtained with another B-ALL cell line (REH-Luc-
mCherry-Puro, data not shown). To determine the effect of TSLP on the growth of B-ALL 
cells we used a B-ALL cell line CALL4 that previously had been described to be sensitive 
for TSLP (Tasian et al., 2012). Since these cells, in contrast to NALM-6 and REH, had 
not been transduced with Luciferase, we used Presto Blue® as a means to determine 
the amount of viable cells. In contrast to Tasian and colleagues, who observed a 
significant increase in the number of CALL4 even upon addition of only 10 ng/ml of TSLP 
(Tasian et al., 2012), we did not observe significant expansion of CALL-4 cells upon 
stimulation with TSLP (Figure 9C and data not shown). Even when using different initial 
amounts of B-ALL cells (0.3; 0.6 and 0.9x10^6 cells/ml), RPMI medium with different 
percentages of FBS (0, 10 and 20%), other B-ALL cell lines (NALM-6-Luc-mCherry-Puro 
and RS4;11) and different time points (3 and 6 days) (data not shown) we did not observe 
any expansion of B-ALL cells upon adding either 10 or 100 ng/ml of TSLP. 
Although we were not able to demonstrate that TSLP induces growth of CALL4 cells and 
some of assays above were only performed once, these data confirm previous reports 
that B-ALL cells are responsive to both IL-7 and CXCL12 (Juarez et al., 2003, 2007a; 
Mowafi et al., 2008; Sbaa-Ketata et al., 2001). 
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Figure 9 - B-ALL cell lines are functionally responsive to IL-7 and CXCL12, but not to TSLP. (A) 
Migration of NALM-6-Luc-GFP cells (NALM-6) in response to CXCL12 (100 ng/ml) within 3h at 37°C 
incubation. The results are normalized to luminescence of a well in which the cells (5x10^5 cells) were 
directly placed in the lower well (i.e. 100% migration). AMD3100 (10 µg/ml) is a drug that blocks CXCR4 
signalling. Values represent one independent experiment. (B) Expansion of B-ALL cell line NALM-6-Luc-
mCherry-Puro (NALM-6) after treatment with IL-7. B-ALL cell line NALM-6-Luc-mCherry-Puro (3X10^4 
cells/ml) was cultured in the presence of different amounts of BM MSCs, with or without IL-7 (100 ng/ml) 
during three days. Luminescence was analysed and fold induction (FI) in relation to luminescence on day 0 
was calculated. Results represent duplicates of one experiment. (C) Growth of CALL4 cells (6x10^5 cells/ml) 
after treatment with different concentrations of TSLP for 3 days. The amount of viable cells was determined 
by measuring the fluorescence obtained using PrestoBlue® Cell Viability Reagent. ns = non-significant (p 
>.05), Mann-Whitney two-tailed test. Results represent the average of three independent experiments. 
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3.1.3. Constitutive KD CXCL12 BM-MSCs are able to form bone in 
vivo 
As the factors of our interest are produced by BM MSCs, we could nicely and more 
accurately determine their biological importance by decreasing or ablating their gene 
expression in BM MSCs. Therefore, we previously generated constitutive (ct) knock 
down (KD) BM MSCs for CXCL12, IL-7 and TSLP and validated successful knock down 
using qRT PCR (for all three factors) and ELISA (for CXCL12) (Anne van der Leun, 
unpublished). A prerequisite for use of these cells to allow study of the in vivo role of 
these factors in the homing, engraftment and growth of B-ALL cells is that they should 
allow generation of an ectopic human BM microenvironment under the skin of 
immunodeficient mice. 
In order to test that, ctKD MSCs were seeded onto scaffolds, implanted into mice and 
tested for bone forming capacity by staining paraffin embedded tissue sections with 
Haematoxylin & Eosin (H&E) staining (Figure 10A). Not only wild type (wt) MSCs were 
able to form bone, but also Scr ctKD MSCs maintained this ability. In two out of three 
scaffolds seeded with CXCL12 ctKD MSCs, MSCs were still able to form bone to a similar 
extent as the controls. The IL-7 ctKD MSCs showed only modest bone formation in one 
out of the three mice, and TSLP KD MSCs were unable to form bone in any of the mice. 
(Figure 10B). Constitutive VCAM-1 KD BM MSCs were also unable to form bone in vivo 
(data not shown; by Jessica Sigmans and Regina de Jong). Taken together, these 
results show that Scr and CXCL12 KD MSCs were able to form bone in vivo, indicating 
that on itself lentiviral infection does not affect the bone forming capacity of MSCs. 
Unfortunately TSLP, VCAM-1 or IL-7 KD MSCs lack in vivo bone forming ability, 
indicating that depending on the gene that is being knocked down, MSCs will either keep 
or lose their bone forming ability.  
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(previous page) Figure 10 – CXCL12 constitutive KD MSCs are able to form bone in vivo. (A) Schematic 
representation of the scaffold model. RAG2-/-γc-/- mice were implanted with wild type (wt), Scrambled (Scr) 
or CXCL12, IL-7 or TSLP constitutive (ct) KD MSC-loaded BCP scaffolds. (B) Representative images of 
Hematoxylin & Eosin staining of the scaffolds at eight weeks post implantation. Results are representative 
of three scaffolds each implanted in different mice. S = scaffold; B = bone. 
 
3.1.4. Generation of inducible KD MSCs 
One possible reason for the inability of the constitutive KD MSCs to form bone might be 
that the factors that are knocked down are crucial for the process of bone formation. To 
overcome this problem we used a system to knock down these factors in an inducible 
way, which should allow us to first form bone and only then induce knock down of the 
respective genes. 
 
3.1.4.1. Cloning of the inducible KD vectors 
We have used the pH1tet-flex/FH1t(INSR)UTP vector system that allows inducible knock 
down of gene expression by short hairpin RNAs (shRNAs). In this system, the promoter 
that leads to the transcription of the shRNAs is regulated by DOX using a H1 promoter 
(H1)-driven tetracycline (tet) operator (tetO) and a Ubiquitin promoter(Ub)-driven tet 
resistance operon repressor (tetR, Figure 11). 
The final lentiviral vector pFH1t(INSR)UTP does neither contain the H1 promoter nor 
tetO, so we had to clone those sequences, as well as the gene specific shRNAs, into the 
final vector. For this purpose, we used an intermediary vector pH1tet-flex which contains 
H1, tetO and cloning sites (BbsI/XhoI) for the insertion of the shRNA-oligos. For the 
design of the shRNA-oligos we inserted a BbsI overhang and a XhoI recognition site 
flanking the sense, loop and anti-sense sequences taken from (previously validated) 
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shRNA vectors of the Mission TRC shRNA library from Sigma (Fig 11B). The H1tet-
shRNA cassette was amplified by PCR and digested with PacI to be inserted into PacI-
digested pFH1t(INSR)UTP. 
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(previous page) Figure 11 - Schematics and cloning strategy of the inducible knock down system. (A) 
Schematic representation of the mechanism of action of the lentiviral vector. Briefly, the human H1 promoter 
of RNA polymerase III (H1) with a tetracycline (tet) operator (tetO) sequence are upstream to the shRNA. 
The tetracycline resistance operon repressor (tetR) and puromycin are constitutively transcribed as they are 
downstream the Ubiquitin promoter (Ub). When tetR binds to tetO, the tetR represses the transcription of 
the shRNA. Upon addition of the inducer doxycycline (DOX), DOX binds to tetO competing away tetR and 
leading to transcription of the shRNA (Seibler et al., 2007; van de Wetering et al., 2003). (B) Schematic 
representation of the cloning strategy to generate inducible KD shRNAs. (C) Main components of the final 
lentiviral vector FH1t(shRNA)UTP. 
 
3.1.4.2. Validation of CXCL12 inducible KD in BM MSCs 
With the generated vectors, we produced lentivirus and transduced BM MSCs that were 
then selected with Puromycin (CXCL12, VCAM-1 and IL-7 indKD MSCs) or based on 
GFP expression (Scr KD MSCs).  
To evaluate the efficiency of the knock down in CXCL12 indKD MSCs, we performed 
qRT-PCR to determine the CXCL12 mRNA expression levels and, since CXCL12 is 
secreted by BM MSCs, ELISA to quantify protein levels. The expression of CXCL12 
mRNA in CXCL12 indKD MSCs was substantially decreased in the KD cells in the 
presence of DOX (approximately 50% in comparison to indScr1 with DOX) (Figure 12A). 
However, the low expression of CXCL12 was already observed in CXCL12 indKD MSCs 
without DOX addition. Similar to the mRNA level, the secretion of CXCL12 protein in one 
of the non-targeting vectors (Scr1) was reduced upon treatment with DOX (20% 
reduction), whereas the other (Scr2) MSCs showed a higher expression of CXCL12 after 
DOX treatment (37% increase, not tested at the mRNA level, Figure 12B). Nevertheless, 
when no DOX was added, both Scr1 and Scr2 had a similar expression of CXCL12 
(approximately 440 pg/ml), suggesting that this effect is dependent on DOX and that 
these cells behave in a similar way before addition of DOX. Since we already observed 
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CXCL12 downregulation in CXCL12 indKD MSCs without DOX addition (almost 55% 
reduction when compared to CXCL12 protein levels in Scr1 and Scr2 MSCs in the 
absence of DOX) similarly to the CXCL12 mRNA levels in the same condition, we 
hypothesized that there could potentially be leakiness in the inducible system, i.e. that 
there is a substance present in the culture medium (MSC medium with PL) that already 
inhibits the binding of tetR to tetO, resulting in the transcription of the shRNAs. To 
investigate if there was leakiness in the system, we analysed the CXCL12 mRNA 
expression when the cells were cultured in a medium containing a type of FBS that had 
been shown by Patrick Derksen’s group (UMC Utrecht) to be free of DOX-like 
substances (DOX free medium). Surprisingly, in this DOX free medium the levels of 
CXCL12 mRNA were already decreased in untreated CXCL12 indKD MSCs (Figure 
12C), similar to the CXCL12 mRNA levels in PL containing medium. No clear differences 
in CXCL12 mRNA levels were observed for Scr1 indKD MSCs in between the two culture 
media. 
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(previous page) Figure 12 – Validation of BM MSCs with inducible KD of CXCL12. (A) Scrambled1 (Scr1) 
and CXCL12 inducible KD MSCs (D06) were cultured for 16h in medium with Platelet Lysate (PL) in the 
presence of 0.25 ng/ml Doxycycline (DOX). Total RNA was extracted from each condition and CXCL12 
mRNA levels were quantified by qRT-PCR. Results are expressed as relative expression to Scr1 without 
DOX. The results represent one experiment (lines) performed in triplicate (dots). (B) Scr1, Scr2 and inducible 
KD CXCL12 MSCs were cultured for 7 days in medium with PL in the presence of 0.25 ng/ml DOX. DOX 
was added every two days. Cells were then cultured (35,000 cells per well in a 24 well plate) for 3 days in 
the presence of DOX. Cultured medium was collected and CXCL12 expression was quantified by ELISA. 
The results represent the average of one experiment performed in duplicate. (C) After 48h in the presence 
of DOX (0.25 ng/ml) in MSC medium with DOX free FBS or PL, total RNA was extracted and CXCL12 mRNA 
expression was quantified by qRT-PCR. Results are expressed as relative expression to Scr1 without DOX 
and represent the average (lines) of two independent experiments (dots) each performed in triplicate. 
 
In conclusion, in cells that are lentivirally transduced with shRNAs vectors targeting 
CXCL12 there is a DOX-independent reduction of CXCL12 both at the mRNA and protein 
level suggesting that either the DOX free medium is still leaky or that there is an error in 
the lentiviral vector used for knocking down CXCL12. However, since other inducible 
shRNA vectors did not show any sign of leakiness in DOX free medium (Derksen et al. 
unpublished, and see below), an error in the CXCL12 indKD vector is the most plausible 
explanation. 
 
3.1.4.3. Validation of inducible VCAM-1 KD in BM MSCs 
To determine if the BM MSCs lentivirally transduced with shRNA targeting VCAM-1 had 
inducible downregulation of the expression of VCAM-1 protein, we used flow cytometry. 
We cultured Scr1, Scr2 and VCAM-1 indKD MSCs in the presence of DOX (1 ng/ml) for 
3 days, after which we stained the cells with PerCP labelled human anti-CD106 (VCAM-
1). In standard culture conditions, the expression of VCAM-1 was very low, being only 
slightly higher than in the isotype controls (Scr1 and VCAM-1 indKD) or even below 
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(Scr2) (Figure 13A). However, it was promising to already observe a decrease in the 
expression of VCAM-1 in VCAM-1 indKD MSCs upon DOX treatment (29% reduction in 
comparison to untreated VCAM-1 indKD MSCs). To more definitely show DOX-induced 
VCAM-1 down-regulation, we tested DOX-induced VCAM-1 downregulation in VCAM-1 
indKD MSCs that were stimulated with Tumor Necrosis Factor-alpha (TNFα), a cytokine 
that via the NF-κB signalling pathway induces the up-regulation of VCAM-1 (Uchibori et 
al., 2012; Xiao et al., 2012). We started by optimizing the concentration of TNFα needed 
to obtain a maximal upregulation of VCAM-1 by treating wild type MSCs (D06) for 24h 
with different concentrations of TNFα. The maximum expression of VCAM-1 was already 
achieved with a dose of 5 ng/ml TNFα and higher concentrations of TNFα (10 ng/ml and 
20 ng/ml) induced a similar VCAM-1 up-regulation (data not shown). To assure that the 
maximal upregulation would always be achieved, we decided to hereafter treat the MSCs 
with 10 ng/ml TNFα. In addition, we decreased the incubation time, as the maximal 
upregulation was already observed with 16 to 18 hours of TNFα treatment (data not 
shown). When Scr1, Scr2 and VCAM-1 indKD were treated with TNFα, addition of DOX 
(1 ng/ml) resulted in a dramatic reduction (almost 70%) of VCAM-1 expression on VCAM-
1 indKD MSCs in comparison to both non-targeting MSCs (Figure 13B). To determine if 
we could achieve the same reduction of VCAM-1 expression with lower concentrations 
of DOX and therefore avoid potential secondary effects of DOX addition, we performed 
a titration of DOX. As depicted in Figure 13C, the lowest concentration of DOX 
(0.125ng/ml) already induced the maximal downregulation of VCAM-1. In the follow up 
experiments we used 0.25 ng/ml of DOX to be sure that the maximal decrease of VCAM-
1 expression would always be reached. To determine how long it takes to achieve the 
maximal downregulation of VCAM-1 after DOX addition, we treated both Scr1 and 
VCAM-1 indKD MSCs with DOX for different periods of time (Figure 13D and 13E). To 
assure a relatively constant and sufficient level of DOX, additional DOX was added every 
second day. In contrast to the two previous experiments, the expression of VCAM-1 in 
DOX-treated Scr1 was slightly decreased (21% reduction). The maximal downregulation 
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of VCAM-1 expression in VCAM-1 indKD MSCs (65% downregulation) was reached after 
two days of treatment with DOX and thereafter the expression of VCAM-1 remained 
stable over time. 
To confirm successful VCAM-1 KD as based on flow cytometry, we also analysed the 
effect of DOX on VCAM-1 mRNA expression levels in VCAM-1 indKD MSCs. Taking into 
consideration the results obtained with the CXCL12 indKD MSCs (Figure 12), we also 
wanted to test the optimal medium for culturing the indKD MSCs. Upon DOX treatment, 
the VCAM-1 mRNA expression was reduced when the MSCs were cultured in either PL-
containing MSC medium or in medium with DOX free FBS (Figures 14A and 14B). The 
DOX-induced downregulation of VCAM-1 in VCAM-1 indKD MSCs was approximately 
25 % more efficient when the cells were cultured in DOX free medium than in PL medium 
(75% vs 50% reduction), especially after 5 days treatment (Figure 14A). These results 
suggest that there is no leakiness of the inducible system in either DOX free FBS or PL 
media. Though this experiment was only performed once, culture of VCAM-1 indKD 
MSCs in MSC medium containing our regular FBS (standard), which had not been 
previously tested for potential DOX-like activity,  there was already knock down of VCAM-
1 in the absence of DOX suggesting that a substance that induces the downregulation 
of VCAM-1 is already present in this FBS. To confirm the effect of different culture media 
on VCAM-1 protein levels, we used flow cytometry to analyse the VCAM-1 expression 
on VCAM-1 indKD MSCs that were cultured for 3 days in the different media. In line with 
what was observed at the mRNA level, there was already downregulation of VCAM-1 in 
MSCs cultured in MSC medium with standard FBS without DOX addition. Although, this 
reduction at the protein level was not as dramatic as the downregulation at the mRNA 
level and the experiment was only performed once, these results suggest that standard 
FBS-containing medium is probably not the best medium to culture the indKD MSCs 
cells in. As for the mRNA levels, in the absence of DOX no difference in protein 
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(previous page) Figure 13 - Validation of BM MSCs with inducible KD for VCAM-1. Scrambled1 (Scr1), 
Scrambled2 (Scr2) and VCAM-1 inducible KD MSCs (D06) were cultured in medium with Platelet Lysate 
(PL) in the presence of the indicated concentrations of Doxycycline (DOX). After three days, cells were 
collected and expression of VCAM-1 protein on the cell surface was determined by flow cytometry using an 
anti-human CD106 (VCAM-1) antibody. Cells were treated with TNF-α (10 ng/ml) to induce the VCAM-1 
expression when indicated. Graphs represent one experiment. Representative histograms of untreated (A) 
and TNF-α-treated cells (B) that were treated with 1 ng/ml of Dox. (A) and (B) Graphs represent VCAM-1 
mean fluorescence intensities (MFI) of the indicated cells/conditions. Results represent one experiment. (C) 
VCAM-1 inducible KD MSCs were cultured in the presence of different concentrations of DOX and treated 
with TNF-α (10 ng/ml). Graphs represent relative VCAM-1 expression on VCAM-1 indKD MSCs. Results 
represent one experiment. (D) and (E) Kinetics of VCAM-1 expression in VCAM-1 indKD MSCs as above. 
Cells were cultured for 1-7 days in the presence of DOX (0.25 ng/ml). New DOX was added every two days. 
Graphs represent histograms (D) and MFIs of one experiment (E). 
 
expression in DOX free medium and PL medium was observed, supporting the idea that 
there is no leakiness in either. In addition, the knock down of VCAM-1 was more efficient 
in DOX free medium similar to what we previously observed at the mRNA level. 
Taken together, the DOX free medium is the best medium for culturing the VCAM-1 
indKD cells since this medium prevents leakiness of the system and allows the highest 
level of mRNA/protein down-regulation. 
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Figure 14 - Optimization of culture 
medium to use for VCAM-1 IndKD 
MSCs. (A) VCAM-1 inducible KD MSCs 
were cultured in medium with Doxycycline 
(DOX) free FBS, Platelet Lysate (PL) or 
Hyclone FBS in the presence of 0.25 
ng/ml Doxycycline (DOX). DOX was 
added every two days. Cells were treated 
with TNFα (10 ng/ml) to induce the VCAM-
1 expression 16h before extracting RNA. 
After five days, total RNA was extracted from each condition and VCAM-1 mRNA levels were quantified by 
qRT-PCR. Results are expressed as relative expression to DOX free FBS without DOX. Results represent 
the average (lines) of two experiments (dots) performed in triplicate (for Dox free FBS and PL medium) or 
of triplicates of one experiment (Hyclone FBS medium). (B) After 24h DOX exposure (0.25 ng/ml) in MSC 
medium with DOX free FBS or PL, total RNA was extracted and VCAM-1 mRNA expression was quantified 
by qRT-PCR. TNFα (10 ng/ml) was added 16h before RNA extraction. Results are expressed as relative 
expression as compared to DOX free FBS without DOX and represent the average (lines) of two independent 
experiments (dots) performed in triplicate. (C) VCAM-1 indKD cells were cultured in the presence of DOX 
(0.25 ng/ml) for 3 days in the same conditions as described in (A). Cells were collected and expression of 
VCAM-1 protein on the cell surface was determined by flow cytometry using an anti-human CD106 (VCAM-
1) antibody. The graph represents the mean fluorescence intensity (MFI) of one experiment.  
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3.1.4.4. Functional validation of inducible VCAM-1 KD in BM 
MSCs 
After validating the VCAM-1 indKD MSCs at the mRNA and protein level, we aimed at 
analysing the effect of VCAM-1 knock down in a biological context. Recently, it was 
demonstrated that co-culture of B-ALL cells with MSCs leads to approximately 2.5 fold 
upregulation of VCAM-1 in the BM MCSs (Jacamo et al., 2014). Furthermore, this 
signalling pathway was shown to be necessary to induce NF-kB activation and to trigger 
stroma-mediated chemoresistance. Based on this, we conducted a similar co-culture 
experiment to determine if there was a difference in B-ALL-induced upregulation of 
VCAM-1 between VCAM-1 indKD MSCs and Scr indKD MSCs. Scr1 and VCAM-1 indKD 
MSCs were cultured for 3 days in either the absence or presence of DOX (0.25 ng/ml), 
after which MSCs were plated in a 6 well plate in the presence or absence of DOX. As 
positive control, TNFα (20 ng/ml) was added. NALM-6-Luc-mCherry-Puro cells or 24h 
conditioned medium of this B-ALL cell line were added to the MSCs. 3 days later, the 
expression of VCAM-1 was analysed using flow cytometry. In line with the results 
described above,  TNFα treatment of both Scr1 and VCAM-1 indKD MSCs cells cultured 
in DOX resulted in an up to 12 fold increase of the expression of VCAM-1 in the Scr1 
MSCs, whereas the VCAM-1 indKD MSCs only showed an 3 fold TNFα-mediated VCAM-
1 increase (Figure 15A and 15B). In all conditions and even with both control MSCs, 
DOX addition slightly decreased the expression of VCAM-1. B-ALL cells induced a slight 
increase of the expression of VCAM-1, an effect more evident in the absence of DOX. 
When DOX was added, the expression of VCAM-1 in MSCs co-cultured with B-ALL cells 
was higher in Scr1 MSCs than in VCAM-1 indKD MSCs (1.62 fold versus 1.09 fold), 
suggesting that the KD also prevents upregulation of VCAM-1 in conditions in which 
MSCs are exposed to B-ALL cells. Furthermore, we observed a similar trend upon 
addition of B-ALL conditioned medium, albeit to a lesser extent, suggesting that there 
may be certain soluble factors responsible for this upregulation but that cell-cell contact 
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is also required. In conclusion, though we only performed a pilot experiment and thus it 
should be repeated, co-culturing B-ALL cells with VCAM1 indKD MSCs to investigate the 
biological importance of VCAM1 KD appears to be promising. Albeit B-ALL cells do not 
induce much VCAM-1 expression, we can observe some differences in B-ALL cells-
dependent VCAM1 upregulation between Scr1 and indKD VCAM1 MSCs. Moreover, this 
B-ALL-MSCs interaction may as well influence leukemic cells. Thus, we decided to look 
as well at the effect of VCAM-1 on B-ALL cells. 
 
 
 
 
 
Figure 15 – B-ALL cells induce upregulation of VCAM-1 in BM MSCs. (A) and (B) Scrambled1 (Scr1) 
and VCAM-1 inducible KD VCAM-1 MSCs were cultured for 3 days in Doxycycline (DOX) free medium in 
the presence of 0.25 ng/ml DOX. Cells were harvested and plated in a 6 well plate (100000 cells/well) (-),  
in the presence of TNFα (20ng/ml) (TNFα), B-ALL cell line NALM-6-Luc-mCherry-Puro (57500 cells/well) (B-
ALL cells) or with conditioned medium from NALM-6-Luc-mCherry-Puro cells (0.6x10^6 cells/ml) cultured 
during 24h (Cond med). Cells were also plated in the same conditions in the presence of DOX (0.5ng/ml). 
After 3 days, cells were collected and expression of VCAM-1 protein on the cell surface was determined by 
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flow cytometry using an anti-human CD106 (VCAM-1) antibody. Graphs represent one experiment. (A) 
Representative histograms of TNFα-treated cells and MSCs cultured in the presence of B-ALL cells that 
were treated with 0.5 ng/ml of DOX. (B) VCAM-1 mean fluorescence intensities (MFI) of the indicated 
cells/conditions. (C) NALM-6-Luc-mCherry-Puro cells (3,75x10^4 cells/ml) were cultured on top of wild type 
(wt), Scr and VCAM-1 constitutive KD MSCs. Cells were treated with TNFα (20 ng/ml) to induce the VCAM-
1 expression when indicated. Fold induction (FI) of the luminescence as compared to the luminescence 
obtained on day 0. Results represent duplicates of one independent experiment. 
 
Althogh VCAM-1 has not shown to affect the viability of B-ALL cells (Hsieh et al., 2013), 
we used a co-culture assay to determine if VCAM-1 had any effect on the expansion of 
B-ALL cells. As a pilot experiment, we cultured the B-ALL cell line NALM-6-Luc-mCherry-
Puro in the presence of VCAM-1 ctKD MSCs (these cells were generated by Jessica 
Sigmans, Anton Marten’s lab, and show a 52% KD at the protein level, data not shown). 
We used ctKD instead of indKD because the indKD MSCs require the constant presence 
of DOX in the medium and we first wanted to analyse the effect of VCAM-1 
downregulation only. Briefly, NALM-6 cells were co-cultured with wt MSCs, Scr KD MSCs 
and VCAM-1 ctKD MSCs for 3 days. In some conditions TNFα was added to induce the 
expression of VCAM-1 and therefore potentially more clearly determine possible 
differences between the different MSCs. Expansion of B-ALL cells was analysed by 
adding luciferine and quantifying the luminescence. As previously observed, B-ALL cells 
expanded more in the presence of MSCs than without the stromal support (Figure 15C). 
However, there was no obvious difference between the expansion of B-ALL cells when 
cultured with the different MSCs. In addition, TNFα treatment appeared to have a 
negative effect in B-ALL expansion. This results suggest that VCAM-1 has no effect on 
B-ALL growth. Thus, a better read-out will probably be an adhesion assay, as VCAM-1 
in an adhesion molecule, which will be described later. 
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3.1.4.5. Validation of inducible IL-7 KD in BM MSCs 
Lastly, we also generated inducible IL-7 KD MSCs. To determine if the DOX-inducible 
system also allows inducible downregulation of IL-7, IL-7 mRNA expression in IL-7 indKD 
MSCs was analysed by qRT-PCR. Whereas the IL-7 mRNA levels in Scr1 MSCs didn’t 
vary in the presence of DOX (Figure 16), IL-7 indKD MSCs already presented some 
downregulation of IL-7 without addition of DOX (approximately 50% downregulation), 
suggesting some level of leakiness. Importantly, upon addition of DOX these IL-7 indKD 
MSCs showed a strong decrease in IL-7 expression, which was almost 90% lower than 
the expression in Scr1 MSCs that were not treated with DOX. Comparing the IL-7 mRNA 
expression in these MSCs upon culture in MSC medium with PL or with DOX free 
medium showed a similar level of leakiness and, in contrast to VCAM-1, no improved IL-
7 mRNA downregulation in the DOX free medium¸ suggesting that for these IL-7 IndKD 
MSCs it did not matter which medium was used. 
Figure 16 – Validation of BM MSCs with inducible KD of IL-7. Scramble (Scr1) and IL-7 inducible (ind) 
KD MSCs (D06) were cultured for 48h in medium with Doxycycline (DOX) free FBS or in Platelet Lysate (PL) 
in the presence of 0.25 ng/ml DOX. Total RNA was extracted from each condition and IL-7 mRNA levels 
were quantified by qRT-PCR. Results are expressed as relative expression as compared to Scr1 without 
DOX. Results represent the average (lines) of two independent experiments (dots) performed in triplicate. 
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As already indicated in Figure 9B in which B-ALL cells expanded more when cultured in 
the presence of the combination of MSCs and IL-7 than with either alone, and as 
demonstrated by others (Juarez et al., 2007b), IL-7 has been shown to be a growth factor 
that stimulates expansion of B-ALL cells. This co-culture system is thus ideal to 
functionally validate our IL-7 indKD MSCs. For this purpose, we co-cultured B-ALL cell 
line NALM-6-Luc-mCherry-Puro with wt, Scr1 or IL-7 indKD MSCs, in either the absence 
or presence of DOX (0.5 ng/ml) and/or IL-7 (100 ng/ml) and after 3 days we measured 
the relative B-ALL expansion using luciferine. In agreement with the data presented 
above, B-ALL cells expanded more in the presence of MSCs, an effect which is 
enhanced in combination with IL-7 (Figure 17). No clear differences were observed 
between the growth of NALM-6 cell line co-cultured with wt MSCs and with IL-7 indKD 
MSCs in the absence of DOX (Figure 17A). The presence of DOX had a negative effect 
on B-ALL growth in all conditions that contained MSCs. In MSCs treated with DOX, only 
upon addition of IL-7 could we observe an effect of IL-7 indKD MSCs in B-ALL cells’ 
expansion when compared to wt MSCs, as leukemic cells didn’t proliferate as much with 
the first (Figure 17B). When comparing the support of IL-7 indKD MSCs upon addition of 
DOX, this had a negative effect on the growth of B-ALL cells, slightly overcome by the 
addition of IL-7 (Figure 17C). However, as a negative effect of DOX was already 
observed in wt MSCs (Figure 17A) we cannot conclude whether the effect observed in 
IL-7 indKD MSCs upon DOX addition is solely due to IL-7 downregulation. This 
experiment should thus be repeated to study whether IL-7 downregulation is relevant for 
the expansion of leukemic cells in vitro, since with this pilot experiment we were not able 
observe any considerable difference in the abiltity of IL-7 indKD MSCs to support B-ALL 
cells. 
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Figure 17 - IL-7 inducible KD MSCs are still able to support expansion of B-ALL cell line NALM-6 in 
vitro. B-ALL cell line NALM-6-Luc-mCherry-Puro (3,75x10^4 cells/ml) was cultured in the presence of 
different amounts of wild-type (wt), Scr1 or IL-7 indKD MSCs; with or without IL-7 (100 ng/ml) and in the 
presence or absence of DOX (0.5 ng/ml) for three days. Luminescence was measured and fold induction 
(FI) in relation to luminescence on day 0 was calculated. Graphs represent the effect of DOX (A), IL-7 in 
DOX-treated conditions (B) and the effect of IL-7, DOX and different amounts of IL-7 indKD MSCs (C) on B-
ALL expansion. Results represent one independent experiment performed in duplicate.  
 
3.1.5. In vivo bone formation capacity of inducible KD MSCs 
Now that we have generated MSCs with inducible KD for VCAM-1 and IL-7 and validated 
successful KD, it is necessary to test if they didn’t lose their ability to differentiate towards 
osteoblastic lineage in vivo after the genetic manipulation. If they are able to form bone 
in vivo we can use them to answer our main question: whether these stromal factors are 
crucial for the growth of B-ALL in a humanized niche in vivo. 
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To determine if the ind KD BM MSCs maintained their capacity to form bone in vivo, 
Scr1, VCAM-1 and CXCL12 indKD MSCs were seeded into scaffolds. IL-7 indKD MSCs 
were not taken along because their knock down hadn’t been validated yet when we 
started the experiment. On the other hand, scaffolds seeded with CXCL12 indKD MSCs 
were implanted in mice since by the time we began this experiment we were thinking 
that the KD was working and the reason why CXCL12 was already downregulated 
without DOX addition was because of leakiness in the medium in which cells were 
cultured. 
Figure 18 – In vivo bone formation by inducible VCAM-1 and CXCL12 MSCs. Schematic representation 
of the scaffold model. RAG2-/-γc-/- mice were implanted with Scrambled1 (Scr1) or CXCL12 or VCAM-1 
indKD MSC-loaded BCP scaffolds. Six weeks after implantation, half of the total mice (3/6) were injected 
intraperitoneally twice per week with 125 µg Doxycycline (DOX) and DOX (1 mg/ml) was added to their water 
containing 5% sucrose. Eight weeks after implantation, the formation of bone will be analyzed by 
Hematoxylin & Eosin staining of the scaffolds. Expression of CXCL12 and VCAM-1 mRNA will be analysed 
by qRT-PCR and expression of VCAM-1 by Flow Cytometry. 
 
Six mice were subcutaneously implanted in their dorsal side with six scaffolds seeded 
with Scr1, VCAM-1 and CXCL12 indKD MSCs, two per each type of MSCs (Figure 18). 
Bone formation usually takes six to eight weeks to occur. Therefore, we assumed that 
after 6 weeks the MSCs, if able to differentiate towards osteoblastic lineage, should have 
form bone so we added DOX to half of the mice (3/6) to induce the KD of the stromal 
factors. DOX (125 µg) was intraperitoneally injected twice per week and DOX (1mg/ml) 
was also added to the water, containing 5% sucrose. Eight weeks after the implantation, 
mice will be sacrificied and the scaffolds will be collected. We are planning on fixing half 
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of the scaffolds in 4% formaldehyde to assess through H&E staining the ability of these 
MSCs to form bone in vivo. We will also isolate human cells from the remaining scaffolds 
by flow cytometry using an antibody that recognizes a pan-human antigen (Tra-1-85). 
For VCAM-1 indKD scaffolds, we will analyse the expression of VCAM-1 protein in mice 
treated with DOX and compare it to untreated mice by flow cytometry. Total RNA will be 
extracted from all cells to quantify the mRNA expression of CXCL12 and VCAM-1.  
 
3.2. Generation of Knock out (KO) MSCs using the CRISPR/Cas system 
The use of inducible shRNAs that knock down the expression of our target genes has 
many advantages, as previously described. However, this system has also some 
limitations such as the off-target effects on other mRNAs (Kaelin, 2012) and the inability 
to totally delete the expression of the target gene. Thus, a system which would involve 
genome editing and ablation of a certain gene would allow a clearer study of the 
functional effect of that gene. Recently, a powerful tool for genome engineering became 
available: the CRISPR/Cas system. This is a precise and efficient genome targeting 
technology that is based on guiding an endonuclease (Cas9) to the target DNA sequence 
through a short RNA sequence complementary to this genome region. After the creation 
of double strand breaks by Cas9, naturally occurring cellular DNA repair mechanisms 
are activated which may result in knock out of the gene. Therefore, we here used 
CRISPR/Cas9 vectors targeting CXCL12 and VCAM-1 in order to obtain a full knock out 
of these stromal factors in BM MSCs. 
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3.2.1. Cloning of the CRISPR/Cas9 vectors 
We have used the lentiviral vector pRP-418 generated and kindly provided by Robert 
Jan Lebbink (Emmanuel Wiertz lab, UMCU). This vector contains a gRNA scaffold and 
human codon-optimized Cas9. In addition, it contains the cloning sites EspEI that allow 
the insertion of double strand (ds) oligonucleotides which are complementary to the 
target DNA sequence in the genome. This insert is localized downstream to the U6 
promoter and upstream to the gRNA scaffold (Figure 19). Briefly, the cloning strategy 
consisted of ligating the annealed ds oligonucleotides inserts into EspEI digested pRP-
418 vector (see also material and methods). 
 
Figure 19 – Cloning strategy of CRIPR vectors for generating knock out MSCs. Schematic 
representation of the cloning strategy to generate CRISPR vectors. 
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3.2.2. Lentivirus-mediated CRISPering 
With the generated vectors, we produced lentivirus, transduced BM MSC and selected 
successfully transduced BM MSCs with Puromycin. In addition, we also transduced BM 
MSCs with CD44 CRISPR vectors using lentivirus medium kindly provided by Robert 
Jan Lebbink (UMC Utrecht). 
For all studied genes, we generated CRISPR vectors with RNA sequences targeting 
different regions of the target gene. To determine if the knock out was successful, we 
analysed CD44 and VCAM-1 expression by flow cytometry and CXCL12 secretion 
through ELISA. Two populations of BM MSCs were observed based on their CD44 
protein expression. Most of BM MSCs transduced with CD44 lentivirus vector were CD44 
negative, ranging from 50% to 74% depending on the guide RNA (Fig 20A). VCAM-1 
expression in BM MSCs transduced with VCAM-1 CRISPR vectors was determined after 
treatment with TNFα to stimulate the expression of VCAM-1 protein. Once again, the KO 
was successful and 60% to 82% of MSCs were VCAM-1 negative. To determine if 
CXCL12 KO was effective, CXCL12 KO MSCs were cultured for 3 days after which the 
medium was collected and the secretion of CXCL12 was quantified by ELISA. Lentivirally 
transduced cells secreted approximately 83% less CXCL12 than Scr BM MSCs. Starting 
with lower cell numbers during the transduction gave similar results (data not shown). 
Even though the experiments were only performed once (with the exception of VCAM-1 
KO MSCs in which VCAM-1 protein expression using flow cytometry was analysed twice) 
and therefore should be repeated to obtain full confirmation of the KO of the target genes, 
these data suggests that we were able to successfully generate CD44, VCAM-1 and 
CXCL12 KO BM MSCs. 
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Figure 20 – Successful generation of KO MSCs for CD44, VCAM-1 and CXCL12. (A) CD44 KO MSCs 
(D06) were generated by lentivirus-mediated CRISPering using two different gRNA (tg1 and tg2). Expression 
of CD44 was analysed by flow cytometry using an anti-human CD44 antibody. Results represent one 
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independent experiment. (B) Percentage of CD44 negative cells as determined in (A). (C) Generation of 
VCAM-1 KO MSCs by lentivirus-mediated CRISPering. The KO obtained using three different gRNA (tg1, 
tg2 and tg3) is represented by analysis of the expression of VCAM-1 after 16h of TNFα treatment (10 ng/ml). 
Results are representative of two experiments. (D) Percentage of VCAM-1 negative cells obtained after 
CRISPering using three different target sequences. These results were obtained by gating the graphs as 
indicated in (C). (E) CXCL12 KO MSCs were generated by lentivirus transduction with two different gRNA 
(tg1 and tg2). After transduction and Puromycin selection, cells were cultured (35,000 cells per well in a 24 
well plate) for 3 days. Culture medium was collected and CXCL12 expression was quantified by ELISA. 
Results represent one experiment performed in duplicate.  
 
Since assessing B-ALL expansion upon co-culture of BM MSCs with decreased VCAM-
1 expression did not allow functional validation of VCAM-1 indKD MSCs (Figure 15C) we 
performed a pilot experiment in which we used the newly generated VCAM-1 KO MSCs 
in an adhesion assay to 1) functionally validate these VCAM-1 KO MSCs and 2) to 
develop an assay that allows as well the functional validation of the VCAM-1 indKD 
MSCs. For this purpose, we incubated B-ALL cells with wt MSCs and VCAM-1 KO MSCs 
in the absence or presence of TNFα. After 24h, we determined the amount of B-ALL cells 
that remained adherent to MSCs by quantifying luminescence after addition of luciferine. 
As expected, the adhesion of leukemic cells was higher when these were cultured with 
MSCs than without stromal cells (Figure 21).  Less B-ALL cells adhered when TNFα was 
added. We observed that B-ALL cells in the absence of TNFα adhered approximately 
24% less to VCAM-1 KO MSCs (CR VCAM-1) than to wt MSCs. The same trend was 
observed when a higher number of MSCs was used (data not shown). Upon addition of 
TNFα, such differences are attenuated as there is not an obvious difference between the 
MSCs. Though this experiment should be repeated to verify if this effect is reproducible, 
we were already able to observe a reduction on the adhesion of B-ALL cells to VCAM-1 
KO MSCs in comparison to B-ALL cells co-cultured with wt MSCs, in the absence of 
TNFα.  
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Figure 21 – Reduced NALM-6 adhesion to VCAM-1 KO BM MSCs. NALM-6-Luc-mCherry-Puro cells 
(3,75x10^4 cells/ml) were cultured on top of wild type (wt) and VCAM-1 KO MSCs in the presence of 10 
ng/ml TNFα when indicated. To wash away non adherent cells, every wells were washed twice with PBS. 
New medium was added to these cells and luminescence was analysed. The results represent the duplicates 
of one experiment. 
 
3.2.3. Transfection of MSCs using Neon Electroporation  
Although we were able to efficiently and easily generate BM MSCs knocked out for 
CD44, VCAM-1 and CXCL12 through transduction with lentiviral vectors, this method of 
generating KO MSCs has a few drawbacks. First, since we transduced the MSCs with 
lentivirus, the vector was randomly inserted into the cell’s genome and we cannot predict 
the side effects of this integration. Moreover, Cas9 is being constitutively transcribed 
leading to long and high presence of this endonuclease in the cell, which may lead to off-
target effects (Cho et al., 2014; Cradick et al., 2013). Therefore, a system in which the 
vector wouldn’t be integrated into the genome and with only transient expression of Cas9 
would overcome the drawbacks of lentiviral transduction. We hence tried to transfect 
MSCs with the CRISPR vectors we had generated. 
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Different methods of transfection were tried. In all cases we first transfected the MSCs 
with either a small vector (4,700bp) encoding GFP (sGFP) or with a big (9,289bp) GFP 
vector (bGFP) to have a straightforward read out for the efficiency of transfection by 
analysing GFP expression using microscopy and/or flow cytometry. We used vectors 
with two different lengths because we expected that the shorter one would be more easily 
transfected into MSCs and the longer one is of a similar size as the CRISPR vector. 
For the first transfection, we used a Gene Pulser MXcell™ Electroporation System 
(BioRad). Briefly, MSCs were placed in a sterile 2mm electroporation cuvette and were 
electroporated with 600V, 100 microseconds. Three days after electroporation, the GFP 
expression was analysed using a flow cytometer. Only the MSCs transfected with the 
sGFP vector expressed GFP (4-6%, data not shown). To improve the efficiency, we then 
tried a different method for transfection. As we had been successful in generating 
lentivirus using HEK293T and Poly(ethylenimine) (PEI), which establishes ionic 
interactions with the phosphate backbone of nucleic acids creating compact complexes 
that are taken up by cells via endocytosis (Godbey et al., 1999), we tested PEI 
transfection on MSCs. However, neither an adapted protocol from the one used to 
transfect HEK293T cells nor a protocol available online 
(http://www.cytographica.com/lab/PEItransfect.html) led to GFP expression upon 
transfection of MSCs with either sGFP or bGFP (data not shown). Lastly, we used a 
microcapillary system, the Neon® Transfection System, in which cells are electroporated 
in a pipette tip chamber instead of a cuvette, which allows application of a more uniform 
electric field overcoming the problems faced in standard electroporations, such as low 
efficiency in gene transferring and high cell mortality (Lim et al., 2010; Madeira et al., 
2011; Nishikawa and Huang, 2001). With this method, it was possible to achieve GFP 
expression in MSCs transfected with sGFP one day after microporation in all settings 
tested (Figure 22A). Two days post transfection, we quantified GFP expression in 
transfected MSCs using a flow cytometer. We got the highest level of transfection in 
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setting C (70% of MSCs transfected with sGFP were GFP positive), which was a setting 
in which we gave two short electrical pulses instead of one longer pulse as in settings A 
and B, suggesting that the number of pulses is important in determining the transfection 
efficiency. However, MSCs transfected with bGFP had no GFP expression (data not 
shown). As this was also observed in the standard electroporation, we hypothesized that 
there could be some problem with the bGFP vector, as the vector was kindly given to us 
and we didn’t test it to confirm that it was functional. As the transfection of MSCs with 
sGFP had been highly successful, we decided to microporate low passage wt MSCs 
(D06) with VCAM-1 tg1, VCAM-1 tg3 and CD44 tg2 CRISPR vectors using setting C. 
Two days after transfection, Puromycin was added to select transfected MSCs. Two days 
after Puromycin treatment, the medium was replaced with regular MSC medium. Nearly 
all cells died in all conditions, suggesting that the transfection of MSCs with the 
Puromycin-resistant vectors hadn’t been successful. Even so, we kept the remaining 
cells in culture. Thirty days post transfection, VCAM-1 and CD44 expression was 
analysed by flow cytometry in MSCs transfected with VCAM-1 or CD44 CRISPR vectors, 
respectively. All MSCs transfected with CD44 tg2 CRISPR vector were CD44 positive. 
Likewise, VCAM-1 expression in TNFα-treated MSCs transfected with VCAM-1 CRISPR 
vectors was as high as in the control condition. Taken together, Neon® Transfection is 
a successful transfection method, however, optimization is needed to use this technique 
for CRISPRering. 
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Figure 22 - Successful transfection with GFP, but no successful transfection-mediated CRISPering 
of BM MSCs. (A) and (B) A 4,700bp vector encoding GFP (sGFP) vector was transfected into BM MSCs 
using the Neon Transfection System. Three different electroporation settings were used: A - 1600 V, 20 ms, 
1 pulses; B - 1000 V, 40 ms, 1 pulse; C - 1400 V, 10 ms, 2 pulses. One day after the transfection, microscopy 
images were taken (A). Expression of GFP on sGFP transfected MSCs and on electroporated wild-type (wt) 
MSCs (control) was analysed 48h after transfection by flow cytometry (B). Results represent one 
independent experiment. (C) BM MSCs were transfected with VCAM-1 target (tg) 1 and tg 3 CRISPR vectors 
using setting C. Two days after transfection, Puromycin (1 mg/ml) was added for two days to select for 
transfected cells. 30 days after Puromycin treatment, the expression of VCAM-1 was analysed by flow 
cytometry using an anti-human CD106 antibody. Cells were treated with TNFα (10 ng/ml) 16h before the 
harvesting to increase the expression of VCAM-1. Results represent one independent experiment performed 
in duplicate (A and B). 
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3.3. BM MSCs capacity of forming single clones 
The ultimate goal of CRISPR-mediated generation of KO cells was to generate a pool of 
MSCs in which all cells are knock out for a certain protein. In the case of surface 
molecules, such as VCAM-1, we can easily sort VCAM-1 negative cells by flow 
cytometry. However, this is not the case for CXCL12 KO MSCs or MSCs knock out for 
other soluble MSC-derived factors. There are different methods to measure CXCL12 but 
none allows the detection of CXCL12 at the single cell level while allowing to keep the 
cells alive. First, Western Blot analysis requires cell lysis and CXCL12 is not analysed at 
single cell level. Intracellular FACS allows single cell analysis and even sorting of cells, 
but we would have to permeabilise the cells which would kill them. Furthermore, we don’t 
have a good anti-CXCL12 antibody, since the antibody tested did not show lower 
expression of CXCL12 in CXCL12 ctKD MSCs, which by ELISA were confirmed to 
express lower levels of CXCL12 protein (data not shown). ELISA would overcome the 
problem of killing the cells, but it doesn’t quantify CXCL12 secretion at the single cell 
level. Therefore, the potential solution would be to sort single cells into a 96 well plate 
thus creating single clones of MSCs and expand these. We could then do a screen on 
the clones for CXCL12 expression by ELISA, and then either use the individual clones 
or pool the CXCL12 negative clones, hence generating a polyclonal CXCL12 knock out 
MSC population (see also in the discussion). 
For this strategy to work, we first had to investigate whether BM MSCs were able to 
survive and expand as single cells. To determine their capacity to grow as single clones, 
BM MSCs from two donors (D06 and D99) cells were single sorted into a 96 well plate 
and their growth was followed over time by microscopy. Both types of BM MSCs were 
able to form colonies, but more single cells grew out from D99 cells than from D06 cells 
(Figure 23A, 27 to 40% and 12 to 27%, respectively). Then, to determine if the process 
of lentiviral-mediated VCAM-1 ablation, in VCAM-1 KO MSCs, had any effect on the 
colony forming ability of MSCs, Scr KO MSCs and VCAM-1 KO MSCs were treated with 
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TNFα and single cells were sorted into 96 well plates. For TNFα-treated VCAM-1 KO 
MSCs, we separately sorted VCAM-1 positive and VCAM-1 negative cells (Figure 23B). 
In comparison to wt MSCs, less transduced cells grew out, which could be related to the 
fact that transduced MSCs were of a higher passage than wt MSCs. TNFα treatment had 
no major effect on colony forming ability of VCAM-1 KO MSCs. Importantly, VCAM-1 
negative MSCs showed a slightly improved colony forming ability, indicating that VCAM-
1 negativity does not inhibit the ability of MSCs to grow (Figure 23C). The MSC clones 
that formed big colonies were harvested and VCAM-1 expression was analysed again to 
determine whether these colonies expressed VCAM-1 levels that can be expected based 
on how the cells had been sorted. All VCAM-1 KO MSCs that hadn’t been treated with 
TNFα before sorting didn’t express VCAM-1. As expected, TNFα-treated VCAM-1 
negative KO MSCs remained VCAM-1 negative. In one TNFα-treated VCAM-1 negative 
MSC colony we were able to observe two populations of MSCs, one VCAM-1 negative 
and the other VCAM-1 positive, suggesting that two cells instead of one cell were sorted. 
Furthermore, none of VCAM-1 positive cells survived after harvesting from 96 well plate 
and plating in T25 flask when a big MSC colony was observed. These data suggests that 
single MSC clones are able to expand and that neither lentiviral transduction nor TNFα 
treatment negatively affected the colony forming ability of MSCs. 
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Figure 23 - BM MSCs are able to grow as single clones and are not negatively affected by VCAM-1 
deletion or TNFα treatment. (A) Different passages (as indicated) of BM MSCs from two donors (D06 and 
D99) were sorted into a 96 well plate, (1 cell per well, 95 wells per cell type). The formation of colonies was 
followed by bright field microscopy. The graph presents the percentage of wells with MSC colonies 8-10 
days after the sorting. (B) and (C) BM MSCs that had been lentivirally transduced with scrambled CRISPR 
(Scr) or VCAM-1 CR (VCAM-1 KO MSCs) were treated for 16h with TNFα (10 ng/ml) to induce the 
expression of VCAM-1. VCAM-1 KO MSCs cells were sorted into 96 well plates (1 cell per well, 48 wells per 
cell type) according to their VCAM-1 expression (B). The growth of cells was followed by bright field 
microscopy. The graph presents the percentage of wells with MSC colonies 10 days after the sorting (C). 
Results are representative one experiment. (D) MSC colonies were harvested and cultured for one week. 
Cells were treated with TNFα (10 ng/ml) to induce the VCAM-1 expression 16h before being collected. 
Expression of VCAM-1 was determined by flow cytometry using anti-human CD106 (VCAM-1). The results 
represent one experiment. 
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4. Discussion 
The importance of the BM microenvironment in leukaemia has been extensively studied 
and it has been accepted that the BM plays a crucial role in leukaemia growth, 
chemoresistance and relapse (Tabe and Konopleva, 2014). Nevertheless, further 
understanding is needed and can be provided by novel in vivo models that create BM 
niches that resemble the human BM. Previously, using an human ectopic BM niche 
model in which BCP scaffolds are seeded with MSCs (Groen et al., 2012), we showed 
that primary human B-ALL cells can grow in human ectopic BM niches subcutaneously 
implanted in immunodeficient mice (unpublished data). Taking that into consideration, 
we aimed at demonstrating the importance of CXCL12, IL-7 and VCAM-1 in B-ALL 
growth using the state of the art system that best resembles the human BM niche. With 
this goal in mind we here developed tools to test the role of these stromal factors by 
generating genetically manipulated MSCs in which CXCL12, IL-7 and VCAM-1 are 
downregulated or ablated, that can be used to create ectopic human BM niches. Aiming 
at confirming literature describing the role of these factors on B-ALL in vitro and, mainly, 
at developing in vitro assays to functionally validate the genetically modified MSCs that 
were generated in this study, we used pilot studies to demonstrate that CXCL12 and IL-
7 induce migration and expansion of B-ALL cells, respectively, and that MSCs are able 
to support survival and expansion of B-ALL cells. When MSCs constitutively knocked 
down for CXCL12, IL-7, VCAM-1 and TSLP previously generated and validated at mRNA 
and/or protein level were seeded into scaffolds and implanted in mice to test in vivo bone 
formation capacity, only control and CXCL12 ctKD MSCs were able to form bone. Trying 
to overcome the loss of the ability to form bone, which could be caused by the role of the 
downregulated factors in bone formation, inducible KD MSCs for CXCL12, VCAM-1 and 
IL-7 were generated. Successful inducible KD was confirmed at the mRNA and/or protein 
levels for VCAM-1 and IL-7 indKD MSCs and pilot experiments were performed to 
investigate the functional impact of the KD. Inducible KD of IL-7 didn’t substantially 
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influence the expansion of B-ALL cells. To test the full ablation of VCAM-1 and CXCL12, 
KO MSCs were generated using the CRISPR/Cas system and KO was analysed at the 
protein level. A pilot experiment in which leukemic cells where co-cultured with VCAM-1 
KO MSCs showed that VCAM-1 knock out decreased the adhesion of B-ALL cells to the 
stroma. Testing in vivo bone formation capacity of the genetically manipulated MSCs will 
determine if these MSCs are able to form human ectopic niches in immunodeficient mice. 
Injection of primary B-ALL cells or B-ALL cell lines into mice implanted with scaffolds 
seeded with CXCL12 and VCAM-1 KO MSCs, and/or with IL-7 and VCAM-1 indKD 
MSCs will allow us to determine the importance of the presence of these factors in the 
human BM on leukaemia. 
 
4.1. Response of B-ALL cells to BM stromal cells and stromal factors in 
vitro 
First, we aimed at verifying the importance of BM MSCs in supporting B-ALL cells using 
an in vitro co-culture system, to later also use this to validate the genetically modified 
MSCs. Manabe and colleagues were one of the firsts to demonstrate that BM MSCs 
positively influence B-ALL cell survival (Manabe et al., 1992). Apoptosis of B-ALL cells 
was prevented when these were co-cultured with MSCs. Others have also demonstrated 
a positive influence of stromal support on ALL cell viability (Juarez et al., 2007a). Using 
the cell lines NALM-6 and REH as a model system for B-ALL, we here demonstrated a 
similar effect, as when low numbers of B-ALL cells are cultured in the absence of MSCs 
for 3 days, both B-ALL cells lines decrease in numbers. (Figure 7). This is not a general 
phenomenon, since we are able to culture B-ALL cell lines over long periods of time in 
the absence of stromal cells, as long as leukemic cells are cultured at high density (at 
least 0.3x10^6 cells/ml). While NALM-6 cells expanded in co-culture, addition of BM-
MSCs to REH cells only led to their survival. This discrepancy is in line with previous 
studies that reported that the survival length and stroma contact requirement differs 
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between blast cells from 10 cases of precursor-B-ALL cells (Bradstock et al., 1996). We 
observed that the support of BM MSCs was lost when higher amounts of both MSCs and 
leukemic cells were plated and different MSCs:B-ALL cells ratios were used (data not 
shown). Even though this data may appear contradictory, nutrient exhaustion in the co-
culture system may have contributed to B-ALL cells death when high amounts of MSCs 
were plated or when a very high concentration of B-ALL cells were cultured, whereas 
low numbers of MSCs are insufficient to provide the B-ALL support. Together, these data 
confirm the previously described role of BM MSCs in supporting in vitro expansion and 
survival of B-ALL cell lines. 
Aiming at determining which factors produced by MSCs could be responsible or most 
important for the support of leukemic cells, either in our in vitro co-culture system, or, 
more importantly, in human B-ALL growth in vivo, we initially selected CXCL12, IL-7, 
TSLP and VCAM-1 which have been described to play a role in B-ALL migration, growth 
and survival (Filshie et al., 1998; Juarez et al., 2003, 2007a; Mowafi et al., 2008; Sbaa-
Ketata et al., 2001; Tasian et al., 2012). Our first goal was to determine the specific role 
of these factors on B-ALL cells in vitro by setting up assays to analyse ligand-induced 
receptor downregulation, expansion, adhesion, and migration. Importantly, these assays 
were mainly developed to functionally validate the generated genetically manipulated 
MSCs with decreased expression or ablation of these factors, as will be described below. 
The observation that both NALM-6 and CALL4 down-regulated IL-7Rα upon IL-7 
stimulation was a first indication that these cell lines are intrinsically able to respond to 
IL-7 (Figure 8 and data not shown). Similarly CXCL12-induced CXCR4 downregulation 
showed that CALL4 is also responsive to CXCL12.  
TSLP treatment of CALL4 only led to downregulation of the IL-7Rα subunit of the TSLP 
receptor and not of TSLPR. CALL4 cells express a low to intermediate level of IL-7Rα, 
but a high expression of TSLPR (Chapiro et al., 2010; Tasian et al., 2012), which has 
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been suggested to be a consequence of a TSLPR rearrangement in CALL4. Therefore, 
even if TSLP induces downregulation of TSLPR, the expression levels of this receptor 
subunit are kept very high due to a mechanism independent of the presence of the ligand, 
thus justifying the absence of a noticeable effect of TSLP on TSLPR expression. Looking 
at the functional level, we only observed a minimal CALL4 expansion upon TSLP 
exposure (up to 1.14 fold). It has been previously reported that CALL4 cells show an up 
to 1.4 fold expansion when exposed to TSLP, but we were not able to reproduce this 
even when using similar conditions such as incubation times and TSLP concentrations 
(Tasian et al., 2012) as well as varying concentrations of FBS. We hypothesize that the 
high cell numbers used in our assay explain the lack of effect of TSLP on CALL4 growth, 
as when grown at higher concentrations B-ALL cells seem to be less dependent on 
growth factors. For instance, we also didn’t observe any effect of IL-7 on NALM-6 
expansion when the same high numbers of leukemic cells were used. Only when we 
decreased the amount of NALM-6 cells cultured in the presence of IL-7, an IL-7-
dependent effect on NALM-6 growth was verified (Figure 9B). We therefore should test 
the effect of TSLP on CALL4 in an assay in which lower numbers of CALL4 cells are 
used. To determine the role of TSLP on B-ALL growth in vivo we should then generate 
TSLP indKD MSCs that can be used in our in vivo model. 
In line with previous reports, IL-7 treatment alone also didn’t cause a substantial 
expansion of the B-ALL cell line REH (Brown et al., 2003; Juarez et al., 2007a). IL-7 only 
induced expansion when leukemic cells were exposed to IL-7 in the presence of MSCs. 
This suggests that there may be some factors expressed by BM MSCs that act 
synergistically with IL-7 increasing its effect. In fact, synergistic interactions of IL-7 with 
stem cell factor (Funk et al., 1993; Mcniece et al., 1991) and FLT3L (Hirayama et al., 
1995; Veiby et al., 1996), for instance, result in an increase on the proliferation of B cell 
progenitors and/or B-cell commitment. Mechanisms explaining this synergy have been 
proposed. IL-7 and FL3TL activate parallel but separate proliferation signalling pathways 
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(Åhsberg et al., 2010), and stem cell factor is able to phosphorylate both subunits of the 
IL-7 receptor (γc and IL-7Rα), the first events of IL-7–mediated signalling. Furthermore, 
the combination of IL-7 and CXCL12 leads to optimal growth and survival of leukemic 
cells in vitro (Juarez et al., 2007a). Alternatively, IL-7 may act on MSCs inducing changes 
on the stroma that lead to an increase of B-ALL support, which is supported by the 
observation that MSCs, besides producing IL-7, also express IL-7Rα (Deans and 
Moseley, 2000). Along similar lines, it might be that TSLP, which on its own did not 
significantly impact on B-ALL growth in vitro, could enhance B-ALL growth in combination 
with other MSC-derived factors; something we could actually test if we would perform a 
MSC - B-ALL co-culture experiment in the presence of TSLP. However, for such co-
culture experiment we would first need to Luciferase-label the CALL4 cells, since Presto 
Blue ® cannot distinguish between B-ALL cells and MSCs. 
Though CXCL12 is a chemokine, it has been described to also stimulate proliferation of 
B-ALL cells (Juarez et al., 2007a; Mowafi et al., 2008). We tested this hypothesis using 
two different B-ALL cell lines, NALM-6 and CALL4, of which the first has been widely 
described to be sensitive to CXCL12 (Bradstock et al., 2000). However, we couldn’t 
observe any effect of CXCL12 on leukemic cell expansion in either cell lines (data not 
shown). In line with chemotaxis being CXCL12’s most well-known and accepted function 
(Sipkins et al., 2005a), we observed in a pilot experiment that NALM-6 cells can 
effectively migrate towards CXCL12 (Figure 9A). Although the extent of migration (± 
14%) was lower than previously reported (almost 60%) (Bradstock et al., 2000), this 
could potentially be optimized in future experiments, especially considering that the 
experiment settings were not the same and that we have performed this experiment only 
once and without duplicates. Cell starvation and increasing the time of incubation may 
lead to greater degree of migration of NALM-6 (Bradstock et al., 2000; Hidalgo et al., 
2001). In line with previous reports, AMD3100 addition inhibited the CXCL12 chemotactic 
effect. Though the level of inhibition (almost 80%) was higher than previously described, 
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such differences may be attributed to the type of B-ALL cells that were used in the assay, 
since  Parameswaran et. al observed that, depending on the B-ALL cell type, a different 
level of inhibition was achieved (Parameswaran et al., 2011).  
Taken together, we showed in pilot in vitro assays that leukemic cells respond to CXCL12 
and IL-7 which we can use to validate our genetically manipulated MSCs. Furthermore, 
this preliminary data suggests that these factors may be crucial for B-ALL growth, as 
described in literature.  
 
4.2. Bone forming ability of constitutive KD MSCs 
To confirm the importance of BM-derived factors in a model that more closely resembles 
the human BM, we have generated MSCs lacking these factors as well as VCAM-1, 
which has been described by others to play a role in B-ALL as well (Filshie et al., 1998; 
Hall et al., 2004b), using three different approaches: constitutive knock down, inducible 
knock down and knock out. Use of such MSCs will not only allow in vitro validation, but 
can also be used to address their in vivo role by implantation into mice to form human 
ectopic BM niches. We first tested the bone forming ability of constitutive KD MSCs 
(generated by Anne van der Leun), but only CXCL12 ctKD MSCs had this capacity 
(Figure 10). As previously discussed, ctKD MSCs may have lost the ability to form bone 
because the factors that have been downregulated may be important for osteoblastic 
differentiation. Indeed, in ctKD MSCs, osteoblastic differentiation in vitro was 
compromised (Anne van der Leun, unpublished results). In line with that, Anne van der 
Leun analysed the mRNA levels of IL-7 and TSLP throughout 14 days of osteoblastic 
differentiation of wt MSCs. IL-7 expression reached a peak (4 fold) at day 7 after which 
the levels remained high (2 fold). Likewise, the levels of TSLP increased throughout 
osteoblastic differentiation. This correlation of increased expression of IL-7 and TSLP 
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upon osteoblastic differentiation might suggest that IL-7 and TSLP could be important 
for differentiation of MSCs towards osteoblasts.  
To confirm that the bone formed in the CXCL12 KD MSC-seeded scaffolds showed lower 
CXCL12 expression than the control scaffolds, we tried to develop an 
immunohistochemistry-based detection of CXCL12. However, since the CXCL12 KO 
MSCs that showed an 80% decrease in expression of CXCL12 based on ELISA, showed 
all equally positive for CXCL12 with the anti-CXCL12 antibody used, we thus far have no 
trustable anti-CXCL12 antibody. Although we still need to confirm the CXCL12 knock 
down in vivo in the future using a different immunohistochemistry antibody, the 
observations that CXCL12 ctKD MSCs can form bone in vivo and that CXCL12 is stably 
downregulated in vitro, now allow us to investigate the in vivo role of CXCL12 in the 
migration of B-ALL cells towards the BM niche (see future plans). 
 
4.3. Inducible KD MSCs for stromal factors to study their importance for 
B-ALL growth 
To overcome potential loss of bone forming capacity upon lentivirus-induced knock down 
and to be able to regulate the induction of KD over time, which also would allow us to 
investigate the impact of downregulating stromal factors in different stages of B-ALL 
development, we here used a previously described inducible KD system (Schackmann 
et al., 2011) to target VCAM1, IL-7 and CXCL12 in BM MSCs. 
To allow validation of the VCAM-1 indKD MSCs, we used TNFα treatment to induce 
upregulation of VCAM-1, as without addition of TNFα, VCAM-1 protein expression was 
only slightly higher than the isotype control. As an alternative, we could have 
differentiated the MSCs towards osteoblastic lineage as osteoblasts express high levels 
of VCAM-1 (Zhu et al., 2007). We opted for the TNFα treatment because the osteoblastic 
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differentiation process is technically more laborious and longer (14 days) and because 
MSCs would lose their multipotency. We managed to validate the inducible knock down 
system for VCAM1 indKD MSCs at both mRNA and protein level (Figure 13 and 14). 
VCAM-1 was downregulated at the mRNA level 24h after DOX addition. We saw a nice 
time-dependent decrease of VCAM-1 protein expression by flow cytometry, which 
reached its maximal level of downregulation in 3 days. This DOX-induced decrease was 
an all or nothing event, at least with the doses we tested.  
For the IL-7 indKD MSCs, we confirmed by qRT-PCR that there is downregulation of IL-
7 upon DOX treatment (Figure 16). To further validate the knock down in the IL-7 indKD 
MSCs, we should in the future analyse IL-7 protein expression by techniques such as 
ELISA and Western Blot.  
For the CXCL12 indKD MSCs, there was a DOX-independent reduction of CXCL12 both 
at the mRNA and protein level (Figure 12). We excluded that the medium in which indKD 
MSCs were being cultured was leaky as we compared mRNA and/or protein expression 
of all indKD MSCs cultured in DOX free medium and PL medium and no clear differences 
were observed. Therefore, the most likely reason for this DOX-independent induced 
downregulation is that there is an error in the sequence of the vector. To test this 
hypothesis we can sequence both the original lentiviral vector used to transduce the 
MSCs and the one integrated into the MSCs to check if there is a mistake in the tet 
repressor and/or tet operator. We had planned to functionally validate the CXCL12 indKD 
MSCs by analysing the migration of B-ALL cells toward CXCL12 indKD MSCs 
conditioned medium. However, as we cannot regulate the CXCL12 KD in these MSCs, 
we are not planning on using these CXCL12 indKD MSCs in the future. 
Although our main objective is to use the validated VCAM-1 and IL-7 indKD MSCs to test 
the effect of the respective knock downs in the support of B-ALL cells in vivo, we first 
need to functionally validate the indKD MSCs in vitro and to test their ability to form bone 
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in vivo. In a pilot experiment, aiming at investigating if B-ALL cells interaction with MSCs 
would induce VCAM-1 expression in MSCs, we used flow cytometry to demonstrate that 
Scr1 MSCs co-cultured with B-ALL cells had a slight increase (1.6 fold) in VCAM-1 
expression when compared to Scr1 MSCs cultured in the absence of leukemic cells 
(Figure 15A and 15B). This increase was lower than the previously reported VCAM-1 
upregulation by Jacamo et al. who observed a 2.5 fold increase in VCAM-1 expression 
on B-ALL cell upon co-culture with B-ALL cells. (Jacamo et al., 2014). However, this 
discrepancy might lie in the fact that we analysed VCAM-1 protein expression by flow 
cytometry whereas they quantified the VCAM-1 expression at the mRNA level by qRT-
PCR. Importantly, the effect of the presence of B-ALL cells was not observed in VCAM-
1 indKD MSCs after DOX addition, reconfirming that we have generated MSCs with 
inducible VCAM-1 downregulation. Similarly, we also observed a slight VCAM-1 
upregulation when B-ALL conditioned medium was added to the MSCs, except on DOX-
treated VCAM-1 indKD MSCs, suggesting that one or more substances secreted by 
leukemic cells induce VCAM-1 expression in MSCs. Still, VCAM-1 expression was not 
as high as in the co-culture conditions, suggesting that cell-cell contact is required as 
well. Although addition of exogenous TNFα, IL-1β and IL-4 has been demonstrated to 
induce VCAM-1 expression in BM MSCs (Dittel et al., 1993), it remains undetermined 
which B-ALL derived factor(s) are able to mediate VCAM-1 upregulation in MSCs. 
As we observed that interaction between leukemic cells and MSCs leads to an increase 
of VCAM-1 expression, we next analysed if VCAM-1 knock down in MSCs had any effect 
on support of B-ALL cell both in the absence and presence of TNFα. No considerable 
difference on B-ALL expansion between wt MSCs and VCAM-1 ctKD MSCs was 
observed (Figure 15A), a phenomenon not necessarily unexpected since VCAM-1 
signalling blockade either using anti-functional integrin alpha-4 antibody or anti-human 
VCAM-1 antibody has previously been shown not to inhibit B-ALL growth in a B-ALL – 
MSC co-culture (Hsieh et al., 2013; Mudry et al., 2000). Performing this assay we also 
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observed that TNFα had a negative impact on the expansion of B-ALL cells when in co-
culture, suggesting that TNFα has an inhibitory effect on leukemic cell growth. In fact, 
TNFα has also been shown to inhibit myeloid leukaemia cells expansion (Munker, 1987). 
and TNFα was shown to act synergistically with chemotherapeutic agents increasing 
their anti-tumoral activity (Veen, 2000). Besides, AML cells cultured in medium 
containing, amongst others, TNFα differentiate into dendritic cells which stimulate 
antileukemic cytotoxicity (Choudhury et al., 1999). Together these data suggest that also 
for B-ALL cells TNFα either alone or in combination with factors expressed by MSCs 
might inhibit B-ALL growth. As this TNFα negative impact on leukemic cells was lessened 
when B-ALL cells were cultured in the absence of MSCs, TNFα may instead, or in 
addition, induce some change in the stroma which leads to its decrease on the ability to 
support B-ALL cells. To overcome this issue for the validation of the VCAM-1 indKD 
MSCs, we could instead of TNFα use MSCs which have been stimulated to differentiate 
along the osteoblastic lineage, which also leads to VCAM-1 upregulation.  
Although it has been described in literature that VCAM1 signalling blockade doesn’t 
affect B-ALL expansion, disruption of VCAM-1 binding was shown to decrease stromal-
induced leukemia cell protection during chemotherapy (Mudry et al., 2000). A nice way 
to investigate the effect of VCAM-1 knock down would thus be to test the stromal-induced 
B-ALL support when in the presence of chemotherapeutic agents. In addition, 
considering that VCAM-1 is an adhesion molecule, we could also determine the impact 
of VCAM-1 knock down by analysing the adhesion of leukemic cells to wild type MSCs 
and compare it to the genetically manipulated MSCs. For this method we actually 
performed a first pilot with the newly generated VCAM-1 KO MSCs, as will be discussed 
below. 
Using the assay we had developed in which NALM-6-Luc-mCherry-Puro cells were co-
cultured with MSCs in the absence or presence of IL-7, we showed that IL-7 indKD MSCs 
were still able to support expansion of leukemic cells (Figure 17). Even though the 
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downregulation of IL-7 was of almost 90% (Figure 16), we only observed a slightly 
reduced B-ALL support by IL-7 indKD MSCs upon addition of DOX. However, since DOX 
also induced a certain decrease in B-ALL support when added to co-cultures containing 
either wt or Scr MSCs, it is unclear whether the reduced support by DOX-induced IL-7 
indKD MSCs is either related to IL-7 downregulation or DOX treatment itself. This might 
be related to the fact that IL-7 is secreted in the range of pictograms by MSCs whereas 
induction of B-ALL growth by exogenous addition of IL-7 required a concentration of IL-
7 that was in the nanograms range. Although we expected that adding IL-7 to either 
DOX-treated or untreated IL-7 indKD MSCs would restore their supporting capacity to a 
similar extent as wtMSCs, IL-7 addition to IL-7 indKD MSCs as well as to Scr MSCs 
showed a lower induction of B-ALL expansion upon exogenous IL-7 than wt MSCs. This 
suggests that the lentiviral transduction process and subsequent process required to 
introduce the IL-7 knocking down may have affected other signalling pathways in the 
stromal cells that act synergistically with IL-7. As this experiment was only performed 
once due to time limitations, we plan to repeat it to determine whether it can be used to 
in vitro validate the indKD MSCs and to confirm the in vitro relevance of IL-7 on B-ALL 
growth. For this in vitro validation we also would like to use other B-ALL cell lines, such 
as SEM and NAG8/7 that have been previously reported to be responsive to IL-7 (Friend 
et al., 1994; Greil et al., 1994). To further confirm the role of IL-7, we can treat the MSCs 
with blocking anti-IL-7 antibody, which would be our control to determine the effect of 
blocking IL-7.  
As we aim at using the indKD MSCs to generate human ectopic BM niches to test the 
role of BM-derived factors in the support of B-ALL cell growth, it is crucial that the 
genetically manipulated MSCs are able to form a bone-containing BM microenvironment 
in vivo. To test the ability of indKD MSCs to form bone, we started to test them in our in 
vivo model. Unfortunately, since we will only sacrifice the mice on 10th June 2014, we 
have not been able to report on the results in this thesis. We will not only test the bone 
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forming capacity of the indKD MSCs by H&E staining on paraffin embedded scaffold 
sections, but also determine if there is knock down of the niche factors upon in vivo 
administration of DOX (Reijmers et al., 2010) by qRT PCR and flow cytometry analysis.  
Although we thus far did not succeed in generating CXCL12 indKD MSCs, we 
successfully generated and validated inducible KD MSCs for VCAM-1 and IL-7. We want 
to solve the problem encountered with the CXCL12 indKD MSCs either by regenerating 
these MSCs after checking the sequence of the used vector and/or using a vector 
containing another CXCL12-targeting shRNA. If the on-going experiment will show us 
that indKD MSCs are able to form bone and we can down-regulate the stroma-derived 
factors upon DOX addition in vivo, these will be the ideal tools to test the role of B-ALL 
growth in vivo (see also the conclusions and future perspective section). 
 
4.4. Generation of MSCs KO for VCAM-1 and CXCL12 using the 
CRISPR/Cas system 
These inducible system has many advantages, as stated above, but there are some 
limitations of the shRNA knock down system of which the most important one is the 
incomplete ablation of the gene expression. Therefore, we set out to develop a method 
to generate MSCs which are knock out for a certain gene for which we used the recently 
developed CRISPR/Cas system. Here we show that by using this system we are able to 
generate CXCL12, VCAM-1 and CD44 knock out MSCs (Figure 20). The knock out 
reached was very high for both for VCAM-1 and CD44 (up to 80%), determined by 
analysis of protein expression by flow cytometry. Although we selected transduced cells 
based on puromycin resistance, the DSB created by the Cas 9 does not always lead to 
an incorrect DNA repair that would lead to abrogation of expression of the gene. Hence 
we did not expect a 100% efficiency of the KO. Since we have showed by ELISA that 
CXCL12 KO MSCs secrete approximately 80% less CXCL12 than wt MSCs, we also 
124 
 
assume we successfully created CXCL12 KO MSCs. In the future we plan to use the 
Surveyor Assay Kit or sequencing of single KO MSC clones to test whether we can 
confirm the successful genetic manipulation using CRISPR at the genomic DNA level 
(Cong et al., 2013; Gennequin et al., 2013). Using the Surveyor Assay Kit, the target 
genome sequence is amplified, denaturated and re-annealed with the same amplified 
sequence in non CRISPR cells. As short insertions or deletions are created during the 
repair of DSB in CRISPR cells, the alignment won’t be totally correct. Surveyor is an 
endonuclease that cleaves misaligned single-stranded DNA. If we then run the genomic 
DNA in an electrophoresis gel we can detect the presence of DNA fragments with 
different sizes which indicate the existence of a mutation. 
To functionally validate the VCAM-1 KO MSCs we performed a pilot experiment in which 
we showed that VCAM-1 ablation in MSCs results in decreased B-ALL adherence to 
these cells (Figure 21). Although the reduction was not dramatic and the experiment 
should be repeated not only to confirm the reproducibility of the assay, but also to take 
along the proper control cells (Scr MSCs rather than wt MSCs), our data indicate that 
VCAM-1 deletion affects the ability of B-ALL cells to adhere. This suggests that the low 
level of B-ALL cell-induced VCAM-1 expression, as we have shown above by co-
culturing B-ALL and MSCs after which we analysed VCAM-1 protein expression on 
MSCs by flow cytometry, is sufficient to have a functional impact on B-ALL cells 
adhesion. Moreover, as VCAM1 constitutive KD didn’t influence B-ALL cells expansion, 
the lower number of leukemic cells in the adherence assay was likely not due to a 
decrease in the ability of B-ALL cells to grow. An experiment has been performed by 
others in which they co-cultured the same human B-ALL cell line we used but with a 
murine stromal cell line (Filshie et al., 1998). Though they reached a higher decrease in 
adhesion with the addition of the VCAM-1 antibody blocking than we did with VCAM-1 
KO MSCs (44% versus 23%), we cannot directly compare the experiments as not only 
the method to inhibit VCAM-1 mediated adhesion was different but also the stromal cells 
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had another origin. Still, this experiment showed that B-ALL adhesion can be significantly 
reduced by addition of a VCAM-1 blocking antibody which we can use in future 
experiments as our positive control for decreasing VCAM-1 adhesion. TNFα was added 
to induce VCAM-1 expression and thereby more clearly allow determination of the impact 
of VCAM-1 ablation. In accordance to what was observed for B-ALL expansion, TNFα 
also negatively influenced B-ALL cells adhesion. Also in this adhesion assay, we could 
try the use of VCAM-1 KO MSCs that have been differentiated along the osteoblastic 
lineage, since that also is known to upregulate VCAM-1 expression. In the future, in vivo 
experiments where we implant mice with scaffolds seeded with VCAM-1 KO or VCAM-1 
MSCs, osteoblasts as well as other potential MSC derivatives will be present, thus 
allowing a better and more relevant assessment of the role of stromal-derived VCAM-1 
on B-ALL growth and adhesion (see also below). Together, our data obtained from this 
pilot experiment suggests that this adhesion assay is an elegant method to functionally 
test the effect of deletion or down-regulation of VCAM-1 on B-ALL cells in vitro. 
To functionally validate the effect of CXCL12 ablation on B-ALL cells, we plan to test the 
migration of leukemic cells towards conditioned medium of CXCL12 KO MSCs, using the 
chemotaxis assay in which we showed in a pilot experiment that we can demonstrate 
CXCL12-dependent migration of B-ALL. For this purpose we already collected 
conditioned medium from these MSCs, but due to time limitations we haven’t performed 
the experiment. Since these KO MSCs secrete only 20% of CXCL12 when compared to 
wt MSCs, we expect to obtain a decrease on B-ALL cells migration. 
 
4.5. Transfection of MSCs aiming at generating KO MSCs 
Though we were able to successfully generate KO MSCs by lentiviral-mediated 
transduction of MSCs with CRISPR/Cas vectors, this system has some limitations, 
including the (previously mentioned) lentivirus-mediated random genomic insertion and 
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the constitutive expression of Cas9, increasing the likelihood of the reported off-target 
effects (Cho et al., 2014; Cradick et al., 2013). To overcome such issues we aimed at 
introducing the CRISPR/Cas vector by transfection of MSCs. Despite the use of different 
transfection methods, none has so far allowed the successful generation of KO MSCs. 
The most promising technique was the Neon® Transfection, as both Lim et al. and 
Madeira et al. have demonstrated that it was possible to transfect MSCs with high 
efficiency using Microporation. Using a similar GFP vector and the same Microporation 
settings (settings A and B, respectively), we didn’t obtain transfection efficiencies as high 
as in literature (Figure 22B), which could be due to electroporating a slightly higher 
number of cells, adding a lower amount of DNA (1 µg vs 2 µg in Lim et al.) and/or the 
MSCs being isolated from different tissues (BM vs umbilical cord blood in Lim et al.). The 
highest transfection efficiency we obtained was with setting C that was optimized in our 
lab to transfect IPS cells by Ester Rieter, Paul Coffer lab, UMC Utrecht. The biggest 
difference between setting C and the other settings is the duration and number of pulses, 
suggesting that shorter, but repeated, stimuli increases the efficiency of transfection. 
Nevertheless, transfecting MSCs with CRISPR vectors did not result in decreased 
expression of the respective target genes (Figure 22C). Since the experimental setup 
was similar to the GFP transfection’s, the most likely reason for the poor outcome was 
the vector used for transfecting the MSCs, which was almost 3 times bigger than the 
sGFP vector. Taking into consideration our transfection data and what has been 
described in literature, the microporation efficiency can potentially be optimized in future 
experiments if we increase the amount of DNA and perhaps the number of pulses. We 
could also try different methods of transfection that have been demonstrated to be 
successful such as cationic liposomes (Madeira et al., 2010; Marquez-Curtis et al., 
2013), PEI conjugated with amphipathic bile acids (Moon et al., 2014) or with alginate 
(He et al., 2012). Alternatively, we could also use non-integrating lentiviral vectors 
(Banasik and McCray, 2010; Sarkis et al., 2008) or adenoviruses (Meinel et al., 2006) 
for introduction of the CRISPR/Cas system. 
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4.6. MSCs colony forming ability 
The KO efficiency obtained by lentiviral transduction with CRISPR/Cas vectors is quite 
high, but it would be more accurate to create a population of MSCs with 100% ablation 
of the target genes. For VCAM-1 KO MSCs, this can be achieved by sorting VCAM-1 
negative cells. However, for the detection of VCAM-1 expression, MSCs need to be 
treated with TNFα, which may affect their MSC properties. As a first test, we investigated 
whether TNFα addition negatively influenced colony formation capacity by MSCs. By 
testing in a pilot experiment the ability of TNFα-treated MSCs to survive and expand as 
single cells, our data showed that TNFα treatment had no sizeable effect on MSCs 
colony forming ability (Figure 23C). We further analysed VCAM-1 expression of the 
populations obtained from single clone expansion to confirm that VCAM-1 was ablated 
in these single sorted MSCs, thus checking the cell sorting process based on VCAM-1 
expression and investigating if the cells remained with similar VCAM-1 protein 
expression as before the sorting. We observed that TNFα-treated VCAM-1 negative 
MSCs remained VCAM-1 negative, indicating that it may be possible to generate a pure 
VCAM-1 knock out population of MSCs using this method. We could have drawn a 
stronger conclusion if we had been able to analyse the VCAM-1 expression on VCAM-1 
positive cells to determine if the observed reduction of VCAM-1 expression is not due to 
single MSC clones expansion. Unfortunately, this was not possible as these cells died 
during the expansion process, for thus far unexplained reasons. We can argue whether 
the reason for cells dying was the upregulation of VCAM-1, but since we had similar 
outcomes from two unrelated experiments with different MSCs, we think this was not 
linked to VCAM-1 being highly expressed in these MSCs. All non TNFα-treated single 
clones of VCAM-1 KO MSCs which were able to expand were VCAM-1 negative. As 
80% of VCAM-1 KO MSCs are VCAM-1 negative, it is not surprising that after TNFα 
treatment non TNFα-treated single clones of VCAM-1 KO MSCs don’t express VCAM-1 
as this goes in accordance to probability. In addition, it indicates once again that VCAM-
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1 deletion doesn’t negatively influence the proliferation of MSCs. Besides repeating this 
experiment in the future to confirm the ability of VCAM-1 negative KO MSCs to grow as 
single clones, more tests should be done to verify that these MSCs maintain their 
characteristics after TNFα treatment. Ability to differentiate towards adipocytic and 
osteoblastic lineage, expression of characteristic surface and intracellular markers, 
proliferation capacity and, most importantly, the ability to create an ectopic BM niche in 
vivo are assays that could be performed to characterize these MSCs (Bühring et al., 
2009; Romanov et al., 2005).  
On the other hand, so far we haven’t been able to develop a method in which all MSCs 
are KO for CXCL12. Our data, in which MSCs are able to grow as single clones, supports 
the idea that it may be possible to grow CXCL12 KO MSCs as single clones as well. By 
determining CXCL12 secretion of single clone-derived MSCs populations by ELISA, we 
may be able to generate pure MSC populations with total ablation of CXCL12. To create 
a less homogenous population of CXCL12 KO MSCs, we can pool different populations 
of CXCL12 negative MSCs. It is important to have a more heterogeneous MSC 
population as it was demonstrated that single colony-derived clonal BM MSCs frequently 
don’t possess in vivo bone forming capacity (Prins et al., 2013). 
 
4.7. Final remarks 
In summary, the principal objective of this study is to use genetically manipulated MSCs 
which are knock down or knock out for stroma-derived factors to study their role in B-
ALL growth, survival and migration using our state of the art in vivo model. Through the 
implantation of scaffolds seeded with the inducible KD MSCs into immunodeficient mice 
injected with B-ALL cells, we may be able to answer our main question (see also in 
conclusion and future perspective). Moreover, the importance of the stromal factors 
could be further confirmed if we would use a genetic manipulation system that would 
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enable the total deletion of the stroma-derived factor. Therefore, KO MSCs for CXCL12 
and VCAM-1 using the CRISPR/Cas system were generated, as well as IL-7 KO MSCs. 
So far, we haven’t been able to test if IL-7 is successfully knock out in these MSCs, which 
we are planning to do in the future by ELISA. As we confirmed that the CRISPR/Cas 
vectors we lentivirally transduced into MSCs are functioning, our next step is to generate 
KO MSCs using the same system but by transfection of MSCs. Until this date, we haven’t 
been successful in generating transfected KO MSCs thus we will optimize transfection 
protocols and try different techniques. If succeeding on the generation of such MSCs 
and after isolation of KO MSCs to create a pure KO MSC population, we intend to implant 
as well scaffolds seeded with these MSCs in immunodeficient mice to first test bone 
formation ability in vivo. If this capacity is maintained, we would like to investigate the 
impact of ablation of these stromal factors in B-ALL growth. These studies will contribute 
to further understanding the role of B-ALL cells and stroma interactions for B-ALL growth 
and thereby open doors to new and more effective therapeutic approaches. 
 
 
 
 
 
 
 
 
 
130 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
131 
 
 
 
 
 
 
Chapter 5  Conclusions and Future Perspectives 
 
 
 
 
 
 
 
 
 
 
 
 
 
132 
 
5. Conclusions and Future Perspectives 
Given the importance of BM stromal cells in providing factors to B-ALL cells which 
contribute to the perpetuation and development of the malignancies, it is vital to examine 
which stromal factors are most important in this support. Gaining insight will allow the 
generation of new and innovative therapies targeting the complex and intricate 
communication amongst them, also taking into account the physiological interactions 
between HSCs and derivatives with stromal cells, leaving these untouched. In order to 
achieve this knowledge, the development of more sophisticated models which resemble 
the human BM niche is required. Key findings in such models will certainly increase not 
only the survival rates but also decrease the cancer relapse, therefore expanding the life 
of B-ALL patients. 
The combination of our state of the art humanized in vivo model with genetically 
manipulated MSCs which are knock down or knock out for stromal factors to determine 
the importance of certain stroma-derived factors in B-ALL growth is very promising. 
Further studies using the tools we have generated are likely to increase the current 
knowledge of the interactions in the B-ALL malignant niche and therefore improve 
existing therapies. 
First, we should have in mind that there are many types of B-ALL that have different 
characteristics (Juárez-Velázquez, 2013). Therefore, the interactions of the B-ALL cells 
with the stromal cells and the dependence of leukemic cells to certain stromal factors 
may vary between them (Civini et al., 2013). Thus, depending on the donor of primary 
B-ALL cells, the outcome and relative importance of the studied stromal factors will 
probably be different. A more complete understanding of the role of these stroma-derived 
factors in B-ALL could be provided if we would test the leukaemia growth of cells derived 
from various patient derived B-ALL cells in the ectopic niches seeded with the genetically 
manipulated MSCs. 
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Using the generated indKD MSCs, we could investigate the in vivo role of these factors 
in B-ALL growth, adhesion and migration (Figure 24A). In a first experiment we would 
like to start KD induction after bone formation and before mice would be injected with 
either a B-ALL cell line luciferase labelled or with primary B-ALL cells (Figure 24B). The 
use of luciferase labelled B-ALL cell lines allows the tracking of the cells, but they are a 
homogeneous population thus they are not fully representative of the disease. Primary 
B-ALL cells are heterogeneous but the transduction of these leukemic cells is not as 
efficient, though some promising methods have been developed (Frecha et al., 2010; 
Mock et al., 2012). Migration of leukemic cells towards the human BM niches would be 
determined by bioluminescence as B-ALL cells would be transduced with luciferase 
(Figure 24C). This effect would be studied in the first phases of B-ALL development and 
analysed based on the localization and intensity of the luminescent signal.  
Going from the assumption that we use a B-ALL cell line in which all B-ALL cells are 
equally sensitive for CXCL12, IL-7 and VCAM-1, the CXCL12 indKD MSCs-derived niche 
is predicted to showed a decreased level of luminenscence than wt or Scr MSCs, as it 
was previously observed by Juarez et al. that the chemotaxis and homing of NALM-6 
cells in femoral BM of NOD/SCID mice was dependent on CXCL12 binding to CXCR4 
(Juarez et al., 2009).  Similarly we predict lower luminescence signals in VCAM-1 indKD 
MSCs, since leukemic cells are believed to adhere less efficiently to VCAM-1 indKD 
MSCs-derived ectopic niches (Filshie et al., 1998). In contrast, leukemic cells are still 
expected to engraft in IL-7 indKD MSCs-derived ectopic niches, thus the 
bioluminescence signal should initially be higher than the other indKD MSCs and more 
similar to control MSCs. However leukemic cells’ growth should be compromised as IL-
7 is an important growth factor (Duyn et al., 1999; Eder et al., 1990, 1996; Juarez et al., 
2007), and thereby the signal intensity in later stages would be less intense than in the 
control MSCs. In addition to analysing bioluminescence, we plan to collect the scaffolds, 
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spleen, bone marrow and blood from the mice to confirm the findings observed by 
bioluminescence by determining the presence of hCD19+ cells by flow cytometry.  
As we can induce the knock down, it would also be interesting to only down-regulate the 
factors after leukemic cells have engrafted in the BM niche to test if the decrease of 
expression of stromal factors would affect the growth of B-ALL cells. Again luciferase 
activity and flow cytometry analysis of scaffolds, spleen, bone marrow and blood would 
be used as our read-out. Though the leukemic cells would be allowed to engraft in the 
ectopic niches, knock down of factors responsible for migration and/or adhesion should 
still have a high impact on B-ALL development as CXCR4 and VLA-4 are crucial for the 
retention of B-ALL cells in the BM (Rettig et al., 2012). Consequently, it is expected that 
B-ALL cells which were present in the scaffold before DOX administration will be 
mobilized to the blood (Figure 24D). Downregulation of growth factors, such as IL-7, will 
likely also have an impact on B-ALL development, but not as evident and immediate. 
This approach, especially when using primary human B-ALL cells, would be the closest 
to the clinical situation as chemotherapeutic agents which block the action of these 
stromal factors, here mimicked by inducible downregulation, are administered after the 
prognosis of leukaemia, thus, after B-ALL cells engraftment and development. This 
experiment would be the first to demonstrate the importance of these stromal factors in 
a system that resembles the human BM microenvironment, thus making a huge 
contribution to furthering our understanding of the cell-cell interactions occurring in the 
malignant niche. 
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Figure 24– Model for B-ALL development in inducible CXCL12, VCAM-1 and IL-7 MSCs. (A) Schematic 
representation of the role of CXCL12, VCAM-1 and IL-7 on migration, adhesion and growth of B-ALL. (B) 
Schematic representation of the mouse model. RAG2-/-γc-/- mice implanted with wild-type (wt), Scrambled 
(Scr), CXCL12, VCAM-1 or IL-7 indKD MSC-loaded BCP scaffolds. Two approaches are represented: 
administration of Doxycycline (DOX) before or after injection of B-ALL cells. (C) and (D) Schematic 
representation of the predicted levels of B-ALL cells present in the scaffolds during the stages of B-ALL 
development on the different humanized ectopic niches when DOX is added either before (C) or after (D) B-
ALL engraftment, and comparison between wt, CXCL12, VCAM-1 and IL-7 indKD MSCs. Relative frequency 
of B-ALL cells present in the blood shortly after DOX addition (D). 
 
In subsequent experiments we could also try to ablate more factors simultaneously, 
which in theory could have a bigger negative effect on the growth of B-ALL cells. 
Accordingly, it has been reported that in vitro the CXCL12 chemotactic effect is enhanced 
by the presence of fibronectin, a component of the ECM to which VLA4 can also bind 
(Sbaa-Ketata et al., 2001). The influence of fibronectin in leukemia is poorly studied, but 
it appears as an interesting target of research as it has been shown to promote 
proliferation of pre-B cell lines in a mechanism dependent on VLA4/VLA5 (Harima et al., 
2008) and VLA4 in turn is modulated by CXCL12 (Hidalgo et al., 2001). Thus, a possibly 
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important and yet not fully understood interaction involving fibronectin, VLA4 and 
CXCL12 (the last two already considered to be relevant in leukaemia and in the 
malignant niche) in ALL may exist and its modulation can be a promising therapeutic 
target. We could use our humanized in vivo model to study this interaction. For this 
purpose, scaffolds seeded with CXCL12 or VCAM-1 indKD or KO MSCs would be 
implanted into mice which would be later injected with B-ALL cells. To test the effect of 
the silencing of both pathways, the mice implanted with CXCL12 indKD or KO MSCs 
could be injected with anti-Integrin alpha4 antibody, Natalizumab, (Hsieh et al., 2013) or 
with anti-VCAM-1 antibody (Filshie et al., 1998). On the other hand, AMD3100, an 
CXCR4 blocking drug, could be administered to mice implanted with VCAM-1 indKD or 
KO MSCs (Yu et al., 2011). 
In addition to studying the effect of simultaneously silencing two or more stromal factors, 
we could investigate the effect of combining stromal factors downregulation or ablation 
with chemotherapy on B-ALL growth. It has been demonstrated that combining 
antagonists or inhibitors of certain stroma-derived factors with chemotherapeutic drugs 
increases the survival of mice transplanted with B-ALL cells (Macanas-Pirard et al., 2012; 
Parameswaran et al., 2011; Yu et al., 2011). Our model is an elegant system to test the 
usefulness of combination treatment with ablation of stromal factors, as the ectopic BM 
would lack the expression of such factors and mice could be injected with 
chemotherapeutic drugs. Importantly, we would be able to test this for the first time in a 
humanized BM environment. Therefore, we could determine which combination would 
be more promising in B-ALL treatment. 
So far we have investigated the negative effect of the stromal derived factors by down-
regulating or ablating them in human MSCs. We hypothesize that if a certain factor is 
crucial for leukaemia growth, its decrease or deletion will have a negative impact on 
cancer proliferation. To complement this study we also could generate MSCs 
overexpressing such factors which would confirm its role on leukaemia expansion. 
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Besides, this is more representative of the clinical situation as in the malignant niche 
several factors have been described that have been upregulated rather than 
downregulated. 
CXCL12, VCAM-1 and IL-7 have also been shown to be also implicated in crucial steps 
of haematopoietic and, in particular, B cell development (Ding and Morrison, 2013; 
Greenbaum et al., 2013; Namen et al., 1988; Zhu et al., 2007), but so far all the studies 
performed in vivo analysed murine rather than human haematopoiesis. Using our newly 
generated tools we could also expand our studies into determining the role of these 
stromal factors in human haematopoiesis. The experimental procedure is similar, the 
main difference being that we would inject mice with human CD34+ cells instead of 
leukemic cells, which previously have previously been shown to nicely engraft in the 
humanized scaffolds (Groen et al., 2012). To analyse haematopoietic support, we would 
then stain sections from paraffin embedded scaffolds with antibodies against markers 
specific of the different haematopoietic lineages. In addition, we could quantify the 
different populations by flow cytometry based approaches. 
We have focused our study on CXCL12, IL-7, VCAM-1 and TSLP. Besides these stromal 
factors, many others have been described in literature. Indeed, it was recently reported 
that a new factor may also contribute to the creation of this special niche for leukemic 
cells: galectin-3 (Fei et al., 2013). This protein is expressed at significantly higher levels 
in BM and peripheral blood of ALL patients as compared to controls. Stromal cells can 
secrete galectin-3, which can later be detected in ALL cells. Furthermore, they showed 
that galectin-3 overexpression promotes chemoresistance. This is an exciting and 
relevant discovery of which the in vivo relevance still needs to be addressed, something 
for which our in vivo model is very well suited.   
Moreover, until now, we have focused on stroma-derived factors that contribute to the 
progression of leukaemia. However, it is important to mention that there are other factors 
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which are able to induce the opposite effect. Interleukin-4 is one of those, in which both 
in vitro and in vivo studies have provided evidence that this cytokine inhibits the 
proliferation of B-ALL cells (Mitchell et al., 1996; Pandrau et al., 1992). Assessing the 
role of IL-4 using our model would be very advantageous as we would be able to confirm 
the importance of IL-4 in a setting more close to the human. These are some examples 
of additional promising factors that we could focus on in the future. In addition to these 
known factors, it is quite likely that new ones will be identified in the forthcoming future, 
for which we can then use our model to study their role in vivo. To determine their 
importance we would generate inducible KD and KO MSCs for these, besides developing 
overexpression systems, all of which would create human ectopic niches ideal to 
determine their role in B-ALL. 
Each system of genetically manipulation we have used has its own advantages: the 
inducible KD system allows the control of the down-regulation, and the CRISPR/Cas 
system, the total deletion of a certain gene. Especially since the KO MSCs, similar to the 
constitutive KD MSCs, may be unable to form bone in vivo, the ultimate system would 
be one that would combine both, thus, an inducible KO CRISPR/Cas system. Several 
approaches could be taken to develop such inducible system. We could for instance 
design a plasmid carrying Cas9 which transcription would be regulated by a Tet operator 
sequence upstream to it, similar to the strategy of the inducible knock down system 
described in this thesis. We would therefore transduce the MSCs with a guideRNA-tetO-
Cas9 plasmid carrying a puromycin-resistant gene. As this vector would be quite big, we 
could alternatively generate two vectors, one with the Cas9 inducible system and the 
other with the guideRNA. In this case, Cas9 would only be expressed upon DOX 
addition, since it is the constant presence of the endonuclease and not of the gRNA that 
leads to off target effects. 
Finally, though this in vivo model allows the study of the human haematopoietic niche in 
the context of normal and malignant haematopoiesis, there is still room for improvement. 
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The BM consists of two niches: the endosteal and the vascular. In this model we are able 
to generate a human endosteal niche but the vascular components rise from murine 
endothelial cells. Thus, the generation of an ectopic BM with both human-derived MSCs 
and endothelial cells would be a more truthful representation of the human BM 
microenvironment. In theory, this could be achieved if we would seed the ceramic 
scaffolds not only with human BM MSCs but also with human endothelial progenitor cells. 
Chen et. al have developed a human extramedullary BM using human BM MSCs and 
human peripheral blood–derived endothelial colony-forming cells in Matrigel, indicating 
that we may be able to generate such ectopic human BM in our in vivo model as well 
(Chen et al., 2012). Use of our ceramic scaffolds would be more advantageous over their 
system as the cells would be better spatially organized as they wouldn’t be encapsulated 
by matrigel and therefore they would more closely resemble the human BM. 
As described, this humanized in vivo model has a lot of potential and allows answering 
many questions which will contribute to furthering understanding of B-ALL and other 
haematopoietic malignancies, as well as normal haematopoiesis. In this study we laid 
the groundwork for such investigation that ultimately will contribute to therapeutic 
advancements. 
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